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ABSTRACT 
Urease of Helicobacter pylori is an important virulence factor implicated in the 
pathogenesis of many clinical conditions, such as chronic gastritis, peptic ulceration, 
and gastric cancer. Many urease inhibitors have been discovered, like 
phosphorodiamidates, hydroxamic acid derivatives, and imidazoles. Despite good 
activities at the enzyme level and excellent kinetic properties most of them have not 
been used as therapeutic agents in vivo because of their side effects, toxicity and 
instability.  
This has led to much attention to focus on exploring the novel urease inhibitory 
activities of natural products because of their low toxicity and good bioavailability. 
Honey, a natural product has been used in folk medicine due to its antitumor, 
antioxidant, antimicrobial and anti-inflammatory properties. The aims of this study 
were to isolate, characterise, purify urease produced by H. pylori and investigate the 
inhibitory effects of solvent honey extracts on its enzymatic activity. 
Urease was found to be both surface-associated and cytoplasmic. Maximum 
cytoplasmic urease activity was found to occur after 72 hr whereas maximum 
extracellular urease activities were found to occur after 96 hr. Characterization of the 
crude cytoplasmic urease revealed optimal activity at a pH of 7.5 and temperature of 
40°C. The kinetic parameters Vmax and Km were 45.32 U ml
-1 and 61.11 mM 
respectively.The honey extracts inhibited the activity of the crude urease in a 
concentration dependent manner. The Lineweaver-Burk plots indicated a non-
competitive type of inhibition against H. pylori urease. The two honey extracts gave 
promising inhibitory activities against urease of H. pylori. Thus the results of this 
study delineates that inhibition of urease can ease development in therapeutic and 
preventative approaches based on the enzymatic activity of this Helicobacter protein. 
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Chapter 1 : INTRODUCTION AND LITERATURE REVIEW 
 
This chapter first gives an overview of Helicobacter pylori and its urease, followed by 
giving four parts of literature review – biochemistry and physiology of the urease, the 
biological implications of H. pylori urease activity and the medical use of honey. 
1.1 Overview  
The bacterium Helicobacter pylori, the well-studied gastric pathogen is unique in its 
ability to colonize the acidic stomach which other gastrointestinal organisms can 
hardly pass through. Helicobacter pylori synthesizes a predominantly active urease 
which allows it to function in the harsh acidic conditions of the stomach and 
accordingly, inhibition of this active urease is an important area of pharmaceutical 
and medical research. H. pylori, one of the most common bacterial pathogens of 
humans causes chronic gastritis, duodenal ulceration, gastric ulcers and gastric 
cancer in later life.  The bacterial urease of H. pylori plays an important role in the 
pathogenesis of these human diseases. The gastric pathogen colonizes the human 
stomach by producing large amounts of urease, which hydrolyzes urea present in 
the gastric lumen which is at a concentration that is approximately equal to that in 
plasma. This reaction generates ammonia which protects the organism by buffering 
the gastric acid. Accordingly, inhibition of urease is a suitable and applicable target 
for development of novel therapies to eradicate H. pylori infection. 
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1.1.1 H. pylori 
H. pylori is a gram-negative, spiral-shaped bacterium with bluntly rounded ends in 
gastric biopsy specimens, measuring 2 to 4 µm in length and 0.5 to 1 µm in width. 
Although usually spiral-shaped when cultured on solid media, the bacterium can 
assume a rod-like shape, though coccoid forms typically predominate after 
prolonged in vitro culture or antibiotic treatment (Dunn et al., 1997; Kusters et al., 
1997).  
The bacterium has 2 to 6 polar-sheathed flagella and exhibits a distinctive bulb at the 
end which is an extension of flagellar sheath (O’Toole et al., 2000). The flagella help 
it move freely in viscous solutions such as the mucus layer that superimposes the 
gastric epithelial cells (O’Toole et al., 2000).  The cell wall of this bacterial pathogen 
has a variety of putative outer membrane proteins. Heat shock protein B (Hsp B) and 
urease are profuse in the outer membrane protein of H. pylori. Studies have revealed 
that HspB and urease are located in the cytoplasm in the early log phase of bacterial 
growth. But, in the late log phase, these two proteins become associated with the 
bacterium surface upon spontaneous lysis of some of the bacteria followed by 
adsorption of the proteins onto the surface of the remaining intact bacteria. This 
process is referred to as altruistic autolysis. The function of this process is not yet 
understood but is thought to aid in protection against environmental stresses thus 
benefiting the remaining viable bacteria in vivo. It is also considered to be crucial in 
pathogenesis (Phadnis et al., 1996). The Lipopolysaccharide (LPS) of this organism 
has been found to have low biological activity but is thought to abet in the 
persistence of infection.  
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Studies by Dunn et al., 1997 revealed that the O specific chain of this pathogen’s 
lipopolysaccharide mimicked Lewis blood group antigen in configuration and this 
molecular mimicry should perhaps contribute to its pathogenesis. 
1.1.2 Genome, plasmids, and strain diversity 
The size of the two sequenced H. pylori genomes ranges from 1.6-1.73 Mbp and the 
G+C composition ranges from 35 to 40%. The determination of the complete 
genome sequence of H. pylori strain 26695 showed the existence of 1,587 genes, 
whereas the genome of strain J99 showed only the presence of 1,491 genes (Alm et 
al., 1999; Boneca et al., 2003). However, both genomes have two copies of the 16S, 
23S, and 5S rRNA genes. 
Quite the opposite of other bacterial pathogens, H. pylori is genetically 
heterogeneous. This genetic heterogeneity is probably an adaptation of the 
pathogen to the harsh acidic conditions of its host (Kuipers et al., 2000). 
Investigations have shown that about 40% of this bacterium’s isolates contain 
plasmids which range in size from 1.5 to 23.3 Kb, though these plasmids do not 
contain recognized virulence factors (Dunn et al., 1997).  The bacterium displays 
significant phenotypic and sequence diversity. Studies by Dunn et al., 1997 indicated 
considerable sequence diversity in multiple genes encoding urease, structural and 
accessory proteins, flagellin, vacuolating cytotoxin and Cag A. 
1.1.3 Urease  
The urease produced by the H. pylori is a well-defined virulence protein. Theories 
suggest that this enzyme contributes to the pathogenesis of this gastrointestinal 
bacterium throughout the time it is present in the stomach. This metal-containing 
enzyme is a key element in the bacterium’s resistance to acidity. 
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 It enables this bacterium to survive in hostile environments of extreme acidity in the 
stomach during colonisation which leads to severe gastric diseases like gastric and 
peptic ulcer, gastric cancer and MALT Lymphoma. The important role that urease 
plays suggests that inhibition of this enzyme might represent a novel opportunity for 
therapeutic intervention in Helicobacter infections, either through the use of a urease 
inhibitor alone or, more likely, in combination with a conventional antibiotic.  
Moreover, the structure and catalytic mechanism of urease are of much interest, 
because of its large enhancement (1014 times faster than the uncatalysed reaction) 
of the rate of urea hydrolysis and the presence of a dinuclear nickel active site with a 
carbamylated lysine residue, which is distinctive amongst hydrolytic enzymes.  
Therefore, understanding the urease inhibition mechanisms may confer the solution 
to a simple and efficacious form of treatment and prevention of colonization. 
Hypotheses assume that the enzyme plays an essential role in the bacterium’s 
colonization of the gastric mucosa; however, the exact mechanism by which this 
occurs remains controversial. The unavailability of a simple, consistent, and high 
yield method of purification of this enzyme has been the main limit in revealing this 
essential role (Dunn et al., 1990). 
1.1.4 Acid resistance mechanism of H. pylori urease 
The ammonia produced is thought to play a role in the gastritis that inevitably follows 
infection. Research has indicated that urease is synthesized constitutively by the 
bacterium accounting for about 15% of protein synthesis; making the enzyme 
dependable for the acid resistance mechanism of H. pylori (Clyne et al., 1995).  
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In view of this, it appears that if acid resistance is eliminated by a selective inhibitor 
of  urease then a novel therapeutic agent for eradication would be available (Weeks 
et al., 2000) which would target the acid resistance mechanism of H. pylori.  
1.1.5 Theories of acid resistance 
The effect of H. pylori’s urease on acid resistance became and is still the most 
studied attribute of bacterial ureases. Urease and acid resistance: Where does it 
take place? At first, it was speculated that that H. pylori’s urease was a surface-
associated protein that was involved in acid resistance of the bacterium leading to 
microenvironmental neutrality (Krishnamurthy et al., 1998). The pH was thought to 
increase through the association of H+ ions with non-charged ammonia released by 
urease activity (Marshall et al., 1990). Marcus and Scott, 2001 later demonstrated 
that the urease was a cytoplasmic enzyme and became surface-associated during 
the stationary-phase, when a considerable proportion of the cells lyse and the 
released urease binds to the surface of non-lysed cells.  
The theory of how urease contributes to acid resistance of H. pylori then moved on 
to a second hypothesis, which postulated that cytoplasmic urease activity was critical 
for acid survival (Voland et al., 2003). Conforming to this hypothesis, the non-
charged, urease-produced ammonia was speculated to leave the cytoplasm and 
bind protons in the periplasm, leading to an increase of the periplasmic pH (Voland 
et al., 2003).  
The third hypothesis speculated that uncharged cytoplasmic urease-produced 
ammonia molecules bind protons in the periplasm, elevating the periplasmic pH and 
preventing protons to reach the cytoplasm (Stingl et al., 2002).  
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This model implied that a putative ammonium transporter would export charged 
ammonium ions from the cytoplasm thus creating a neutral cytoplasm. Though up to 
present, no ammonium transporter has been identified in Helicobacter species 
(Stingl et al., 2002). Though it is now widely accepted that cytoplasmic urease 
protects H. pylori against acidity, there is still a debate about the compartment which 
is buffered by the produced ammonia. 
1.2 BIOCHEMISTRY OF UREASE 
There are many fascinating aspects of urease biochemistry. The following sections 
will discuss what is known about urease assays, kinetic behavior of urease, urease 
structural properties, purification studies, active-site structure and catalytic 
mechanism, properties and functions of urease-related accessory proteins that 
facilitate metallocenter assembly. 
1.2.1 Urease enzymology 
1.2.1.1 Enzymatic cleavage of urea  
Urease (urea amidohydrolase; EC 3.5.1.5) is a nickel dependent enzyme that 
catalyzes the hydrolysis of urea to produce ammonia and carbamate. The product, 
carbamic acid, being unstable undergoes spontaneous hydrolysis to yield a second 
molecule of ammonia and carbonic acid but now in an uncatalyzed reaction.  
NH2CONH2 + H2O   NH3 + NH2COOH 
NH2COOH + H2O   NH3 + H2CO3 
At physiological pH, the produced carbonic acid dissociates into the aqueous 
environment to produce hydroxide ions and the two molecules of ammonia produced 
get in equilibrium with their deprotonated and protonated forms as well.  
Urease 
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The end result of the hydrolysis of urea by this enzyme is increase in pH (Burne and 
Chen, 2000).  
H2CO3     H
+ + HCO3
- 
2 NH3 + 2 H2O    2NH4
+ + 2OH- 
This role of acid neutralization has been associated with pathogenesis of H. pylori 
and has made the urease of this bacterium one of the most carefully analyzed 
ureases in the medical research.  
1.2.1.2 Urease assays 
Several excellent techniques are available for quantitating urease activity and kinetic 
analysis. There are advantages and disadvantages for each method, and these 
different assays are different in their sensitivities, ease of use, and susceptibility to 
interference. Thus, the selection of the best assay method will depend on the 
particular experiment of interest. 
Indophenol assay 
The ammonia released during the reaction can be reacted with phenol-hypochlorite 
at high pH to form indophenol, providing a simple and quantitative 
spectrophotometric assay (Weatherburn, 1967). This method is very sensitive, can 
easily detect <0.02 µmol of ammonia and is very useful in analyzing kinetic behavior. 
Nonetheless, this method has the disadvantage of being a fixed-time-point assay 
which requires multiple samples of each assay. Furthermore, several urease 
inhibitors have been found to interfere with this method. 
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Nesslerization reaction 
It is a fixed-time-point spectrophotometric assay, in which ammonia reacts with 
Nessler reagent, containing KI and HgI, (Sigma ammonia color reagent). Instead of 
the intense blue color observed in the indophenol assay, a two- to four-fold less 
intense orange color develops. This assay is convenient because it is rapid and 
easily performed; however, it has the disadvantage of having low sensitivity and 
interference by cellular components.  
Coupled enzyme assays 
Coupled urease-glutamate dehydrogenase (GDH) assay 
A continuous spectrophotometric assay method which uses glutamate 
dehydrogenase to couple ammonia release to reduced nicotinamide adenine 
dinucleotide oxidation has been widely used (Kaltwasser and Schlegel, 1966). The 
production of ammonia by urease stimulates the oxidation of NADH in this coupled 
enzyme assay and the reaction can be monitored by measuring extinction at 340 
nm. This method can detect 0.003 U of urease per ml (1 U hydrolyzes 1 µmol of urea 
per min), which means that 0.02 µmol of ammonia would be released in 3.3 min from 
a 1-ml reaction.  
In view of that, the coupled enzyme assay and the indophenol assay are generally 
comparable in sensitivity. Nevertheless, some drawbacks to this coupled system 
have been noted (Kaltwasser and Schlegel, 1966). For instance, glutamate 
dehydrogenase has a higher pH optimum (pH 8.3) than most ureases; the coupling 
enzyme may be inhibited by compounds being tested as urease inhibitors; a delay is 
observed in reduced nicotinamide adenine dinucleotide oxidation, requiring that the 
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enzyme rate be approximated by a tangent to the time course; and cellular reduced 
nicotinamide adenine dinucleotide oxidase activity may be present in crude fractions. 
Coupled urease-horseradish peroxidase assay 
The ammonia released by urease remarkably stimulates horseradish peroxidase-
catalyzed peroxidation of o-dianisidine, causing an increase in absorbance at 460 
nm (Stutts and Fridovich, 1964). Drawbacks to the method have also been of 
concern, amongst them are; the nonlinearity of the absorbance changes and the 
requirement for basic buffer conditions (pH 9.3). 
pH indicator assay 
The catalysis of urea hydrolysis by urease results in an increase in pH.  The rate of 
pH change can be monitored spectrophotometrically in the presence of a pH 
indicator such as phenol red (Hamilton-Miller and Gargan, 1979). This assay is very 
convenient and suitable for routine comparison of urease rates, but is not 
recommended for detailed kinetic analysis. In assays containing 7 µg of phenol red 
per ml, a nearly linear change with time at 560 nm was observed between 0.15 and 
0.5 absorbance unit when initiated at pH 6.8 (Mobley et al., 1986). However, a 
serious drawback to this method is that the pH of the assay solution will increase 
during the analysis and affect enzyme activity. 
Potentiometric assays 
 Ammonium ion-selective electrodes are also used to quantitate urease activity by 
directly measuring ammonium ion production (Hamilton-Miller and Gargan 1979; 
Katz, 1964; Montalvo, 1970). One of the drawbacks to the method is low sensitivity 
(0.1 mM ammonium ion is the lower limit), and it does not provide a linear response.  
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A further setback with this electrode is interference by potassium and other 
monovalent ions. A pH-Stat can also be utilized to monitor direct alkalinization in a 
very sensitive way (Blakeley et al, 1969). A pH-Stat is an apparatus that is used to 
maintain a constant pH in an aqueous liquid mixture in which hydrogen ions are 
being liberated or taken up. This method is superb and unaffected by inhibitors; 
nonetheless, no buffer is used in the assay and the ionic strength of the solution 
changes during the analysis, which may possibly affect the activity of the enzyme. 
Urease activity in gels 
Several methods have also been adapted or devised to detect urease activity in 
native agarose or acrylamide gels. The simplest technique is to equilibrate the gel in 
a buffer of pH 6 containing a pH indicator, followed by transfer of the gel to a solution 
containing urea (Blattler et al, 1967). As the urea is hydrolyzed, the pH indicator 
changes color within the gel at the location of the urease activity.  
1.2.1.3 Kinetic properties of Urease 
H. pylori like other ureases exhibit simple Michaelis-Menten-type kinetic behaviour. 
Up to present, there has been no evidence for substrate inhibition or allosteric 
behaviour associated with this enzyme. For the cytoplasmic urease, enzyme activity 
is measured using lysed cells to reduce problems caused by urea or ammonia 
transport across the cytoplasmic membrane.  
Low urease activity is probably due to inhibition of the enzyme in cruder preparations 
by unidentified cellular components. As a general rule, the specific activity of urease 
depends on the state of purification, on the specific activity of the homogeneous 
protein, and on the conditions of assay.  
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However, in most cases, the Km values of highly purified ureases agree quite well 
with the values observed for crude urease extracts; hence, the determination of Km 
values does not require the purified enzyme. But it must be kept in mind that the 
specific activity of urease is strongly pH dependent, as some studies have shown 
urease inhibition by thiols, borate, phosphate, and other buffer components leading 
to inaccurate Km values. 
The urease of H. pylori has been purified and its kinetic parameters have been 
determined by measuring the rates of hydrolysis over a range of urea concentrations 
from 0 to 5 mM at 23°C. The reported values of Km ranged from 0.17 to 0.48 mM of 
urea (Dunn et al., 1990; Evans et al., 1991; Hu and Mobley 1990). Under saturating 
conditions of substrate the purified enzyme has been found to possess specific 
activity ranging from 1,100 to 1,700 µmol of urea/min/mg protein (Dunn et al., 1990; 
Hu and Mobley 1990). 
The Km value of H. pylori urease deserves special mention. The urease of this 
gastrointestinal pathogen has one of the lowest Km values (0.17 mM) of all microbial 
ureases and this reflects a very high affinity for substrate. Since the bacterium 
occupies the gastric mucosal lining, a region where low concentrations of urea are 
supplied from the bloodstream (1.7 to 3.4 mM in urea), this low kinetic constant 
seems to be suitable to the ecological niche of the pathogen as it allows this enzyme 
to function under close to saturation conditions, thus working at its Vmax despite the 
low substrate concentration. 
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1.2.1.4 Urease Inhibitors 
A realistic approach to the control of urease-related pathogenesis of H. pylori 
infections is to exploit potent and highly specific inhibitors of this enzyme. A number 
of classes of urease inhibitors have been discovered and examined for their 
pharmacological value (Mobley and Hausinger, 1989; Rosenstein and Hamilton-
Miller, 1984). Inhibitors of this enzyme thus have potential value in medicine. In view 
of this, the study of urease inhibitors can present insight into selected aspects of the 
enzyme mechanism and active-site structure.  
Substrate analogs 
A number of urea analogs have been studied as urease inhibitors, amongst them are 
alkylated ureas, various thioureas, hydroxyurea, and hydroxamic acids. Crude 
enzyme preparations rather than purified enzymes have mostly been used for 
substrate analog studies. 
Substituted ureas and thioureas 
Alkyl-substituted derivatives of urea have been evaluated for their effect on urease 
activity. The urea analogs tested: methylurea, ethylurea, and phenylurea all gave no 
significant urease inhibition. Studies have shown that despite the close structural 
similarity between urea and thiourea, the latter compound is not a substrate for 
urease. 
Hydroxyurea 
Hydroxyurea is a substrate of the urease. When tested on a urease sample rapid 
inhibition is observed followed by slow recovery of activity as hydroxyurea is 
hydrolyzed (Nakano et al., 1984). 
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Hydroxamic acids 
Hydroxamic acids characterized by a terminal functionality are distinguished 
inhibitors of urease discovered by Kobashi et al. in 1962. They have been examined 
against the ureases of microbial origin. The best-studied hydroxamate is 
acetohydroxamic acid (AHA), and has been shown to inhibit several microbial 
ureases including H. pylori. Hydroxamic acids are excellent metal chelators. 
Spectroscopic studies have shown that the mechanism of inhibition involves binding 
to the active site nickel ion. Hydroxamic acid binds in a time-dependent nature and 
has very slow inhibitor dissociation rate. Kinetic analysis of acetohydroxamic acid 
inhibition have been done and AHA was found to be a reversible, competitive 
inhibitor of urease, with a slow dissociation rate (k-1, 8.4 x 10
-5/s) and a Ki of 
approximately 4 µM at pH 7.0 to 7.1 and 25°C (Mobley and Hausinger, 1989). 
Phosphoroamides 
Phosphoroamides are another class of synthetic inhibitors. There are apparently 
slow, tight-binding inhibitors that are extremely potent inhibitors of urease, actually 
more than AHA (Millner et al., 1982). Several studies have demonstrated the 
inhibition of urease activity by phenylphosphorodiamidate (Kobashi et al., 1985). N-
acyl phosphoric triamides have shown significant urease inhibition in cell extracts of 
many microbes (Kobashi et al., 1985). Phosphoroamide compounds are thought to 
act as transition state analogs because of their tetrahedral geometry that is thought 
to mimic an intermediate state in enzymatic catalysis. Spectroscopic studies have 
shown that phosphoramidate binds to the active site nickel (Mobley and Hausinger, 
1989). 
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Thiols  
Thiol-compounds compete with urea for the active site and appear to inhibit urease 
activity by chelating the nickel atoms involved in the catalysis process. Though they 
are weak inhibitors of urease, they have been very useful for better characterization 
of the enzyme metallocenters (Mobley and Hausinger, 1989). 
1.2.1.5 Mechanism of urease inhibition 
Urease inhibitors can be classified into two major classes based on their modes of 
binding: 
I. Inhibitors that bind in a substrate like or active-site directed mode 
II. Inhibitors that bind in a non-substrate like or mechanism-based directed mode 
(Amtul et al., 2002). 
Substrate –like /Active-site directed inhibitors 
The active site directed inhibitors and their analogs are currently the most studied 
compounds in urease inhibition. These compounds share a common feature, each 
inhibitor bridges the two paramagnetic nickel ions in the active site of the enzyme. 
So, the nickel ions and the amino acid residues in the active site are in an orientation 
similar to those of the substrate of urease. The main examples of the substrate-like 
urease inhibitors are thiourea and hydroxyurea. The majority of the first known 
inhibitors of urease contain strongly basic groups such as mimics of the amide bond 
in the urea molecule. Hydroxamic acid derivatives and phosphazenes are also 
known as substrate-like urease inhibitors (Amtul et al., 2002). 
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                 Thiourea                                                                                  Hydroxyurea 
 Figure 1.1 Structures of some substrate-like urease inhibitors 
Non-substrate like /Mechanism based inhibitors 
With this class of inhibitors, there is no close structural similarity between non-
substrate like inhibitors and the enzyme’s substrate (urea). Rather they are designed 
to interfere with the enzyme’s mechanism of action leading to enzyme inactivation. 
The mechanism-based inhibitors are unreactive compounds with structures 
dissimilar to the substrate or the product of the target enzyme. Typical examples of 
this class are phosphorodiamidates and imidazoles (Amtul et al., 2002).  
The enzyme converts them into reactive forms, which then inactivates the target 
enzyme, prior to its release from the active site.ref. Mechanism-based inhibitors have 
shown a lot of potential in drug design. They have a lot of advantages over 
competitive reversible inhibitors. This is because their steady-state concentrations do 
not need to be maintained in order to sustain the inhibitory effects since they are 
generally irreversible inhibitors.  
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1.2.1.6 Inhibitory concentration 
The inhibitory concentration (IC) is the concentration of a substance that causes a 
defined inhibition of a given system. The inhibitory potential of an inhibitor is 
described either as the concentration of an inhibitor at which the enzyme activity falls 
to 50 % of its original value or as the molar concentration of the compound required 
to inhibit 50% of the urease activity i.e. IC50. The IC50 values are similar to the Ki 
(enzyme inhibitor equilibrium dissociation constant) values; but, the correlation 
between these depends on the mode of inhibition, the enzyme concentration and the 
substrate concentration (Tsou, 1988). Thus IC50 values are not a good measure of 
efficacy. 
Nonetheless, IC50 values are not very helpful in giving insights into the mechanism of 
inhibition, provided standard equilibrium conditions are reached. If the type of 
inhibition is also known, then the overall dissociation constant for inhibitor binding 
could be related to their IC50 values by taking into account the substrate and enzyme 
(Mobley and Hausinger, 1989). In contrast, the ratio of inhibitor binding(Ks)  and 
dissociation(K6) i.e. (Ks/K6)  is a useful measure of efficacy when comparing different 
inhibitors. 
1.2.2 Structure of urease 
In 1926, James Sumner demonstrated that urease could be isolated and crystallized 
in pure form, a prestigious piece of work never accomplished by any person up till at 
that time. His research also showed that the pure urease was a protein. This was the 
first investigational proof that an enzyme is a protein, which was a very controversial 
question at the time. The protein structure of urease from Klebsiella aerogenes was 
then first solved in 1995 by Andrew Karplus using X-ray crystal technology (Jabri et 
al., 1995).  
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Since then several other structures of the enzyme have been determined, including 
urease structures from Helicobacter pylori (Ha et al., 2001). Additional insights into 
the structure of urease are available from work in other organisms. 
1.2.2.1 Primary structure 
The urease of H. pylori is a two-subunit enzyme. H. pylori urease consists of two 
different structural subunits of 61.7 kDa (α) and 26.5 kDa (β), unlike most other 
microbial ureases that have three different structural subunits (α, β and γ) and the 
plant urease, jack bean urease that is a single polypeptide (Hu and Mobley, 1990). 
The primary structure of the enzyme is conserved among all H. pylori species. Evans 
et al., 1991 supposed that the H. pylori urease forms a huge complex whose 
molecular mass is estimated to be ~ 600 kDa. The enzyme has appeared under 
transmission electron microscopy (TEM) as a complex structure with a diameter of 
13 nm that displays a three-fold rotational symmetry (Austin et al., 1992). 
1.2.2.2 Quaternary structure 
The urease of H. pylori is a heteropolymeric enzyme that possesses a native Mr of 
380,000 to 600,000 (Hu and Mobley, 1990). There are no differences in subunit 
stoichiometries in this two-subunit enzyme. The urease of H. pylori possesses equal 
numbers of each of the distinct subunit polypeptides. Though there are differences in 
quaternary structure between eukaryotes and prokaryotes, all urease sequences are 
highly conserved and the metallocenters are thought to be identical. The metal ions 
seem to be deeply buried in the enzyme in such a way that they are inaccessible to 
chelators. This raises the question of how the metals and the carbamate become 
incorporated into the protein. 
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1.2.2.3 Crystal structure 
The crystal structure of H. pylori urease has been determined and found to be a 
giant 1.1 MDa , [(UreAB) 3]4 supramolecular assembly of α- and β-subunits.  
 
Figure 1.2 Crystal structure of H. pylori urease (Adapted from Ha et al., 2001)  
 
Each UreAB catalytic unit contains a buried dinuclear nickel active site (Ha et al., 
2001). Structure-based investigators have postulated that this molecular design is 
adapted for acid resistance allowing the survival of the enzyme at low pH. This 
complex enzyme structure together with the low Km value of this enzyme is likely to 
allow this gastrointestinal bacterium to effectively inhabit the host niche.  
1.2.3 Urease metallocenter assembly  
The moment the bacterium enters the gastric mucosal lining, the assembly of the 
urease metalloenzyme commences. The synthesis of a catalytically active urease is 
a laborious process, requiring the presence of two structural proteins, nickel (Ni) 
ions, accessory proteins (UreEFGH), carbon dioxide (for carbamylation) and GTP.  
19 
 
The accessory proteins (UreFGH) are crucial for urease activity (Ferrero et al., 
1992), while UreE delivers nickel to the urease apoprotein complex. UreG is a GTP-
binding accessory protein that is part of the urease enzyme complex, functioning in 
the energy-dependent assembly of the holoenzyme (Moncrief and Hausinger, 1997). 
UreH polypeptide is thought to stabilize the apourease (Park et al., 1994) whereas 
the UreF polypeptide aids in the carbamylation of the Ni2+-bridging lysine residue 
and prevents premature binding of Ni2+ to the active site (Moncrief and Hausinger, 
1996). The hydrogenase accessory proteins HypA and HypB, encoded by hypA and 
hypB in a separate gene cluster, are needed for Ni2+ insertion into hydrogenase 
(Olson et al., 2001). Ni2+ ions are imported into H. pylori cells via NixA, a high-affinity 
metal permease. The transport protein is a 331 amino acid, 37 kDa integral 
membrane protein composed of eight transmembrane domains (Fulkerson et al., 
1998). 
1.2.3.1 In vitro activation of urease apoprotein 
Studies of the H. pylori GroES homologue carried out by Kansau and colleagues 
have shown that ribosomal synthesis and chaperonin-facilitated folding of the urease 
apoprotein UreAB initiate urease activation (Kansau et al., 1996).  UreAB forms 
complexes with the UreF, UreG, and UreH accessory proteins, encoded adjacent to 
the structural genes in the ureABIEFGH cluster (Moncrief and Hausinger, 1997, 
1996; Park et al., 1994; Park and Hausinger, 1995; Soriano and Hausinger, 1999). 
Seemingly, following ribosomal synthesis and chaperonin-assisted folding of UreAB, 
the structure of the newly formed apoprotein is identical to that of the native enzyme, 
apart from lacking nickel and carbamylation.  
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The apoprotein subsequently forms a series of complexes with the three essential 
urease accessory proteins, UreFGH, already in complex with each other. Figure 1.3 
shows the current understanding of the key events in cellular urease activation.  
The urease apoprotein-UreFGH exhibits GTP-dependent urease activation 
associated with a nucleotide-binding site located on the UreG component in the 
presence of nickel ions. Ni2+ delivery to the urease apoprotein-UreFGH complex is 
thought to occur via the metallochaperone, UreE through interaction between UreE 
and UreG. It is at this point that the enzyme complex becomes fully activated. The 
CO2, Ni-UreE, and GTP-dependent activation process results in production of the 
urease holoprotein and dissociation of the accessory proteins. 
 
Figure 1.3 Model for synthesis of active H. pylori urease (Mulrooney and Hausinger, 2003). 
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1.2.4  Active-site studies of urease 
Site-directed mutagenesis experiments (Martin and Hausinger, 1992; Park and 
Hausinger 1993; Sriwanthana et al., 1993), apoprotein activation studies (Park and 
Hausinger 1995), and structural determinations by X-ray crystallography (Jabri et al., 
1995) have given a comprehensive view of the urease catalytic center.  
H. pylori urease had previously been considered to be a hexamer on the basis of 
size-exclusion chromatography. The H. pylori urease is apparently a dodecamer 
protein, consisting of α and β-subunits (Ha et al., 2001). The active site of this 
enzyme has been found to be located in the UreB subunit.  
It consists of amino acid residues found throughout the primary structure that have 
been brought into proximity in the tertiary structure (Jabri et al., 1995).  The enzyme 
is a metalloenzyme whose active site possesses two nickel ions in the β-subunit 
correctly positioned 3.5 Å apart. The amino acid residues of H. pylori UreB subunit: 
His-136, His-138, Lys-219, His-248, His-274, and Asp-362 strongly coordinate with 
the nickel ions and come in direct contact with the urea and a water molecule within 
the active site. His-322 is near the active site and in close proximity to the ions acting 
as a general base in the catalysis. The active site of the H. pylori urease contains 
seven histidine residues and one cysteine residue which also aid in the binding of 
the nickel ions (Labigne et al, 1991). Figure 1.4 shows a close view around the 
active site of the urease. Red is the histidine residue, Yellow: Cys 321 (aa 123 of 
UreB), Blue ball: nickel ion. There are seven histidine residues and one cysteine 
residue around two nickel ions. His 136, 138, 248, and 274 strongly coordinate with 
the nickel ions. His 221 and 323 locates very close to the ions. Cys 321 is also 
present in a close position to the ions.  
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Figure 1.4 Active site of H. pylori urease (Adapted from Fujii et al., 2004). 
The structure of H. pylori urease was determined by Ha et al. (2001). However, the 
knowledge on this urease active site was provided by the crystal structures resolved 
for bacterial urease from Klebsiella aerogenes (Chang et al., 2004). 
1.2.4.1 Urease mechanism 
The mechanism for urease catalysis follows the scheme proposed by Zerner and 
colleagues for the plant urease (Dixon et al., 1980). The ligands to the bi-nuclear 
metallocenter in the urease include a bridging lysine carbamate, a partially bridging 
water molecule, four histidine imidazoles with two bound to each nickel ion, and an 
aspartic acid residue bound to one nickel ion (Jabri et al., 1995, Park and Hausinger 
1993, Park and Hausinger 1995, Wang et al., 1994). Urea is suggested to bind in O-
coordination to one nickel ion facilitated by His-221, resulting in polarization of the 
urea carbonyl group. A carboxylate group has been suggested to stabilize a 
particular tautomer of the bound substrate.  
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The amino acid residue His-219 not shown in the figure is thought to further stabilize 
substrate binding.  Nucleophilic attack on the urea carbonyl by the metal-coordinated 
hydroxyl group gives rise to a tetrahedral intermediate that decomposes to 
carbamate with elimination of ammonia. The water then displaces the carbamate 
completing the cycle. His-320, which is in close proximity to the ions acts as a 
general base by activating the water molecule (or hydroxyl group) which is 
coordinated to the second nickel ion (Mobley et al., 1995). 
1.3 PHYSIOLOGY OF UREASE 
The complete genomic sequence of H. pylori (Tomb et al., 1997) has given further 
insight into the studies of physiology and metabolism of this interesting pathogen. 
Several investigations have shown that H. pylori lacks most of the biosynthetic 
pathways generally found in less specialized bacteria, such as many enteric bacteria 
(Doig et al.,1999; Tomb et al., 1997).  Genomic comparisons and metabolic studies 
have further deduced that H. pylori has a metabolic route which lacks biosynthetic 
pathways for some amino acids.  
So, H. pylori only grows in chemically defined medium supplemented with amino 
acids arginine, histidine, isoleucine, leucine, methionine, phenylalanine and valine, 
and some strains also require alanine and/or serine (Nedenskov, 1994; Reynolds 
and Penn, 1994). H. pylori has the capacity to catabolize glucose. Genomic and 
metabolic reports show that H. pylori cannot utilize any other sugars either 
fermentatively or oxidatively. However, the pathogen exhibits glucose kinase activity, 
which is associated with cell membrane-bound enzymes for the pentose phosphate 
pathway (Doig et al., 1999; Dunn et al., 1997). The lack of genes encoding the 
corresponding enzymes for these metabolic routes has been implicated with such 
biochemical deficiencies (Berg et al., 1997; Kelly, 2001). 
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1.3.1 Urease regulation 
Genes encoding urease of H. pylori have been amplified, cloned and sequenced. 
Urease has till recently been regarded as a constitutive and permanently active 
enzyme. However, recent advances have shown that urease activity of this 
gastrointestinal pathogen is subtly modulated at different levels. 
  Regulatory mechanisms 
i. The expression of the UreA and UreB structural subunits is regulated by 
acidity and the nickel-responsive transcriptional regulator, NikR. 
ii. Ni2+ incorporation mediated by the urease accessory proteins, UreEFGH 
(expression modulated by pH-dependent mRNA stability), and two of the 
hydrogenase accessory proteins, HypA and HypB 
iii. The availability of Ni2+ in the cytoplasm is influenced by the NixA importer (the 
expression of which is down-regulated under acidic conditions) and the 
amount of histidine-rich proteins such as Hpn (the expression of which is up-
regulated by NikR) and possibly by HspA. 
iv. The availability of urease substrate, urea, which is controlled via the acid-
gated UreI urea channel (Stingl and De Reuse, 2005). 
1.3.2 Enzyme location 
The outer membrane of this pathogen has an extraordinary property; it has the ability 
to incorporate urease which is strictly cytoplasmic in other bacteria (Hawtin et al., 
1990). Interestingly, considering that urease is a large oligomeric protein (Austin et 
al., 1992) one would normally not expect it to traverse the bacterial outer membrane.  
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Cryo-immunolocalization techniques have shown that the enzyme is strictly 
cytoplasmic in early log-phase growth of H. pylori. At the end of the log-phase, a 
significant fraction of this protein becomes surface associated or extracellular 
(Phadnis et al., 1996).  
Other proteins of this pathogen are known to have specific secretion pathways, but 
the mechanism whereby urease, become associated with the cell surface is 
controversial. Amazingly, unlike other bacterial ureases which are cytoplasmic, H. 
pylori urease is exported. Also noteworthy is that the export of these ureases 
requires the presence of a nucleotide consensus leader sequence which is absent 
from both H. pylori urease subunits (Clayton et al., 1990). In species of 
Enterobacteriaceae, this lack of a consensus leader sequence results in confinement 
of urease in the cytoplasm. This implies that this bacterium may possibly have a 
distinct pathway for the export of urease subunits. It will be of startling interest to 
establish whether this pathway is limited to the urease subunits or is generally 
applicable to H. pylori proteins. Studies by Cussac et al. 1992 and Ferrero et al. 
1992 have suggested that since the urease of this pathogen lacks leader peptides, 
alternative transport mechanisms must exist. Investigations by Phadnis et al. 1996 
have shown that urease of H. pylori, is an intrinsic cytoplasmic protein in log-phase 
bacteria. This protein becomes surface-associated when it is secreted from the 
cytoplasm by autolysis. 
1.3.3 Urea availability 
The liver is an organ that synthesizes urea which is found in serum, saliva, and 
gastric juice at low concentrations (about 10 mM). However, it is excreted at high 
concentrations (400 to 500 mM) in urine (Griffith et al., 1976).  
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The arginase (RocF)-mediated hydrolysis of L-arginine to L-ornithine also supplies 
urea to H. pylori though in little amounts (McGee et al., 1999). Weeks et al. 2000 
demonstrated that the protein, UreI seems to form a urea-specific pore in the 
cytoplasmic membrane. This channel regulates urea availability to cytoplasmic 
urease by opening at low pH and closing at high pH. 
1.3.4 Use of ammonia generated by urea hydrolysis 
Ammonia generated by urea hydrolysis is assimilated into protein and other 
nitrogenous compounds by a single pathway (Reitzer and Magasanik, 1987). 
Glutamine synthetase (EC 6.3.1.2) catalyzes the reaction: 
 
NH3 + glutamate + ATP    glutamine + ADP + Pi 
Glutamine produced serves as nitrogen donor for other nitrogenous compounds. i.e. 
histidine, serine, tryptophan, AMP, and glucosamine 6-phosphate. It is postulated 
that glutamine synthetase is crucial for viability and nitrogen assimilation in H. pylori 
(Garner et al., 1998). To confirm this, glutamine synthetase-deficient mutants 
generated by allelic exchange could not be isolated.  
1.3.5 Nickel transport 
Generally each active site of urease contains two nickel ions. Since H. pylori urease 
has six active sites then it has 12 nickel ions. H. pylori has a high-affinity system to 
acquire nickel ions which is adapted to overcome the nickel limitation that probably 
occurs in the host. Ni2+ ions are thought to be transported into H. pylori by at least 
two mechanisms. 
 
Glutamine synthetase 
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i. A cytoplasmic membrane-bound protein, NixA which transports nickel ions 
with a KT of 11.3 nM (Mobley et al., 1995). Topology studies by Fulkerson and 
Mobley (2000) revealed that the protein has eight transmembrane domains 
and a periplasmic loop with both the N terminus and C terminus residing in 
the cytosol. Negatively charged residues of Glu, Asp and His which are 
located in the transmembrane domains were found to be crucial for active 
transport of nickel ions (Fulkerson et al., 1998). 
ii. A mutant in which nixA was insertionally inactivated showed a significant 
decrease in both the rate of nickel transport and urease activity following 
culture in vitro (Bauerfeind et al., 1996). Since nickel transport and urease 
activity were not fully abolished in nixA mutants, these findings puts forward 
the possibility of a second mechanism of nickel transport that has yet to be 
elucidated.  
1.3.6 Metal-binding proteins that may affect urease activity 
Bauerfeind et al. 1996 showed that catalytic activity of urease requires Ni2+ ions, 
nevertheless; a H. pylori nixA mutant still retained some urease activity though at a 
reduced rate. These findings showed that auxiliary proteins are likely to be involved 
in nickel binding or transport. There are proteins of H. pylori that have been identified 
with predicted nickel-binding or general metal-binding properties. 
i. Hpn, a protein of 60 amino acid residues long with a molecular size of 7.1 kDa 
(Gilbert et al., 1995). Histidyls alone constitute 47% of the protein’s residues 
making Hpn a strong binder of nickel and zinc ions. So Hpn might be used to 
activate urease. 
28 
 
ii.  A P-type ATPase of 686-amino acid residues long known as CadA has been 
identified in H. pylori (Melchers et al., 1996). It contains segments rich in 
histidine, methionine, glutamate, and aspartate residues at the N terminus 
which may act as a nickel-binding domain. This ATPase has been revealed to 
be a heavy metal ion (Cd2+, Zn2+, Co2+) exporter which exploits ATP as an 
energy source for transport. Mutation of the gene encoding the CadA appears 
to diminish but not abolish urease activity. These findings thus suggest that 
this protein contributes to high levels of urease activity by exporting divalent 
metal cations that may interfere with Ni2+-metalloenzyme formation (Herrmann 
et al., 1999). 
iii. HspA (heat shock protein A), a protein of 118 amino acid residues long has 
been identified in H. pylori. Mutation of the gene encoding the HspA appears 
to be lethal for H. pylori. For this reason, the role of this heat shock protein in 
urease activity cannot be tested directly in the native organism. However, 
expression studies of hspA in E. coli have resulted in slight increase of urease 
activity, signifying that HspA may possibly affect urease activity in wild-type H. 
pylori (Suerbaum et al., 1994). 
 1.4 MOLECULAR PATHOGENESIS 
 
1.4.1 Urease as virulence factor in gastrointestinal infections 
A urease-positive bacterium, H. pylori, discovered 28 years ago, has remained the 
most prevalent infectious agent in the world. Urease is central to the virulence 
elicited by this bacterium. The involvement of this metalloenzyme in gastritis and 
peptic ulceration has been well documented (Cover and Blaser, 1995).  
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Helicobacter pylori urease has been identified as a novel virulence factor, leading to 
the production of pro-inflammatory cytokines. This protein could thus be a future 
target of therapy since there is no ideal first-line eradication of H. pylori infection. 
1.4.2 Urease as an antigen 
Urease, the most prominent protein component of H. pylori (Dunn et al., 1997), 
serves as a powerful immunogen for this organism (Czinn et al., 1989). Patients with 
active gastritis due to H. pylori show significantly elevated immunoglobulins G and A 
along with urease in serum when compared with preinfected levels. Enzyme-linked 
immunosorbent assay systems have been developed to measure these immune 
responses (Perez-Perez and Dunn, 1989). Such tests are useful for diagnosing 
acute infection, monitoring level of H. pylori during the antibiotic therapy and for 
epidemiological studies. 
1.4.3 Avoidance of host defense 
Urease is one of the bacterial factors critical for H. pylori colonization of the gastric 
mucosa (Eaton et al., 1991). H. pylori is relatively sensitive to low pH in-vitro (Hazell 
and Lee, 1985), unless urea is present (Marshall et al., 1988). The colonization of 
the gastric mucosa with a low pH (i.e. pH ≤ 3) would be intricate for the organism 
unless it has the capacity to protect itself from the hostile acid conditions.  
It appears that the bacterium hydrolyzes urea to ammonia, which neutralizes acid 
and allowing survival and initial colonization. To confirm this, urease-negative 
mutants of H. pylori have been constructed by chemical mutagenesis (Perez-Perez 
and Dunn, 1989; Hazell and Lee, 1985); by selection of naturally occurring mutants 
(Marshall et al., 1988); by allelic exchange of in-vitro constructed deletion mutations 
(Blaser et al., 1990).  
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1.4.4 Direct toxicity to the host 
Ammonium hydroxide generated by urea hydrolysis has been found to contribute 
significantly to histologic damage. The damage actually results from the hydroxide 
ions produced by the equilibration of ammonia with water. Studies to demonstrate 
the role of urease in the cytotoxic effects on human gastric adenocarcinoma cell line 
have been done (Hazell and Lee, 1985).  Cell viability was established to be 
inversely proportional to ammonia concentrations generated by urea hydrolysis. 
However, cell viability was enhanced when the urease inhibitor acetohydroxamic 
acid (AHA) was incubated with the culture before the exposure to H. pylori. 
Acetohydroxamic acid was shown to slow down the release of ammonia and reduce 
the cytotoxic effect. These findings suggested that the histological damage observed 
might be a direct result of localized ammonia generated by urea hydrolysis (Hazell 
and Lee, 1985). 
1.4.5 Host damage induced by the immune response 
This enzyme may damage the gastric epithelium via its interaction with the immune 
system. Suzuki et al. 1992 demonstrated that H. pylori cells have the ability to 
stimulate an oxidative burst in human neutrophils.  
When rabbit fetal gastric mucosal cells were incubated with neutrophils, H. pylori and 
urea, shrunken gastric cells were observed which evidenced cytotoxicity. In another 
study, urea-free medium incubated with the inhibitor AHA no cytotoxicity effects were 
observed.  
These findings suggested that H2O2 from the oxidative burst in neutrophils causes 
the oxidation of the chlorine ions which then react with ammonia generated by urea 
hydrolysis to give the highly toxic monochloroamine.  
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The in vitro cytotoxicity activity of urease towards gastric epithelial cells could be 
mimicked by the addition of monochloroamine to the cells. 
 The enzyme itself was shown to activate monocytes and polymorphonuclear 
leukocytes and stimulate them to produce inflammatory cytokines. The secreted 
inflammatory cytokines play a role in mediating the inflammatory response in the 
gastric epithelium. This recruitment of inflammatory response cells thus leads to an 
in indirect damage to the gastric epithelial cells (Harris et al., 1996). 
1.5 DIAGNOSTIC TESTS FOR H. PYLORI INFECTION 
Since H. pylori is implicated in several gastrointestinal conditions, the demand for 
treatment of infection, and the interest for reliable diagnostic tests have increased 
tremendously. However, the choice of test depends on issues such as cost, 
availability, clinical situation and factors such as the use of use of antibiotics which 
may influence the test results. The diagnostic tests are classified as either invasive 
or non-invasive.  
Invasive tests are those that require an endoscopic biopsy of gastric mucosa i.e. 
culture, histological examination, rapid urease test, polymerase chain reaction (PCR) 
of biopsy samples and Fluorescence in situ hybridization (FISH). Under non-invasive 
tests are serology, 13C- and 14C- urea breath tests or stool antigen assays, dental 
plaque and saliva PCR assays. 
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1.5.1  Invasive techniques 
1.5.1.1 Culture  
H. pylori is cultured in a variety of selective (Skirrow’s supplement) and non-selective 
(chocolate agar) commercially available media (Mobley et al., 2003). The criterion 
should be followed as close as possible because sensitivity can be affected by 
sampling methods, sub-optimal laboratory conditions, delayed transport of biopsy 
samples or even exposure to air (Moayyedi and Dixon 1998). There are, however, 
clear drawbacks that should be considered i.e. to culture H. pylori is complicated, 
time-consuming and endoscopy is costly, and requires trained and motivated 
personnel. However, it is the only method which permits determination of 
antimicrobial susceptibility (Buckley and O’Morain, 1998).  
1.5.1.2 Histology 
Histologic analysis of biopsy samples is common and accepted all over the world as 
the “gold standard” for accurate diagnosis of H. pylori infection. Histopathology in H. 
pylori identification also allows for the determination of the degree of inflammation, 
and the presence/absence of MALT-lymphoma and gastric cancers in patients 
(Hardin and Wright, 2002). This method is generally more sensitive than culture and 
it allows direct visualization of organism and extent of the nature of tissue 
involvement. However, limitations can arise if inadequate numbers of biopsy 
specimens are obtained, or if there is a failure to obtain specimens from different 
areas of the stomach (Hardin and Wright, 2002). 
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1.5.1.3 Rapid urease test 
The basis of this test is that H. pylori produces urease in abundance. In an H. pylori 
infected patient, urease is produced beneath the gastric mucus layer where it is 
protected from luminal acid and remains fully active. If urease is present in the 
specimen it will cleave the urea into ammonia and carbon dioxide. The ammonia 
released results in pH elevation which is detected and shown by a colour change in 
a pH indicator.  The test is inexpensive, fast, widely available, accurate and easy to 
perform. However, the sensitivity of the test depends on the bacterial load in the 
stomach (Burette, 1998). 
1.5.1.4 Polymerase chain reaction 
Polymerase chain reaction (PCR) is useful in research, particularly in molecular 
epidemiology and finger printing H. pylori isolates. With PCR, H. pylori can be 
identified in small samples with only a few bacteria present (Hardin and Wright, 
2002). If the target sequence is present in the sample tissue then H. pylori DNA will 
be amplified. PCR assays have shown high sensitivities and specificities on DNA 
fragments from the ureA, ureC, and 16SrRNA. Like any method there are drawbacks 
i.e. only few laboratories can carry out such assays, and test accuracy is easily 
affected by the target DNA and choice of primers, specimen preparation, bacterial 
density, and technical issues regarding the PCR protocol (Dunn et al., 1997). 
1.5.1.5 Fluorescence in situ hybridization (FISH) 
This method is an established non-culture dependent molecular technique that 
simultaneously detects the presence of H. pylori. The technique is used to detect 
and localize the presence or absence of specific DNA sequences on chromosomes 
through hybridization or fluorescence-labeled DNA probes to denatured 
chromosomal DNA (Demiray et al., 2006).  
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FISH uses fluorescent molecules to brightly mark genes on chromosomes. Short 
sequences of single stranded DNA, called probes, which are complementary to the 
DNA sequences that researchers wish to mark and examine are prepared. These 
probes hybridize to the complementary DNA. Since the probes are labeled with 
fluorescent tags this enables researchers to spot the location of those sequences of 
DNA (Demiray et al., 2006).  
There are many advantages of FISH over other diagnostic tests. Firstly, the use of 
the rRNA-targeted fluorescence-labeled oligonucleotide probes for determination of 
antibiotic susceptibility gives the clinician essential information needed to make a 
proper treatment recommendation (Demiray et al., 2006). Secondly, FISH is a highly 
sensitive, reliable, specific and fast technique for the diagnosis of H. pylori infection 
such that test results are available within 3 h after an endoscopy. Thirdly, the probes 
used are commercially available, and the technique can be applied in any laboratory 
without the need for special equipment and facilities, apart from a fluorescence 
microscope (Demiray et al., 2006). 
1.5.2 Non-invasive testing 
Several non-invasive methods for detection of H. pylori infection are available like 
serology, urea breath test, and stool antigen test. 
1.5.2.1 Serology tests 
These tests are based on the fact that infection of the gastric mucosa with H. pylori 
results in immune responses. The responses include elevated levels of specific IgA 
and IgG in serum and elevated levels of secretory IgG and IgM in the stomach (Dunn 
et al., 1997). There are a variety of serological tests known to date, however most 
tests available commercially are enzyme-linked immunosorbent assays (ELISA) 
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(Dominguez–Bello et al., 2001). These tests are however less reliable and are not 
recommended for clinical use. Although these tests are fast, simple and relatively 
inexpensive none of the tests for IgM and IgA to diagnose H. pylori infection have 
been officially approved.  
The sensitivity and specificity of these tests have been too low for them to be 
recommended. Non-specific cross-reactions also give false positive results. As of 
such it is recommended that antibody tests be used only as screening tests, and that 
a positive or negative result depending on the state of the patient being examined 
should be confirmed (Mobley et al., 2003). 
1.5.2.2 Stool antigen testing 
H. pylori infection can be identified by detection of H. pylori protein antigens (HpSA) 
in stool. Enzyme immunoassay kits are used for the detection of these protein 
antigens. The stool antigen test is of high importance as a diagnostic test in children 
because it is easy to perform, reliable and non-invasive (Van Doorn et al., 2001). 
Because of the fastidious nature of H. pylori, culturing the bacterium from stool has 
proven tedious and with a very low yield. The high sensitivity of PCR allows 
detection of the organism even when it is present in low numbers. However, a major 
drawback of this diagnostic technique is the high incidence of false negative results 
which are caused by inhibition factors that are present in stool (Van Doorn et al., 
2001). 
1.5.2.3 Urea breath test (UBT) 
Although H. pylori itself cannot be detected noninvasively, its urease activity can be 
detected by way of a breath test just like with the rapid urease test. In order to detect 
gastric urease, urea that is radioactively labeled with 13C and 14C- is ingested.  
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If H. pylori urease is present, urea is split into NH4+ and 13CO2 or 
14CO2, which can 
be detected in the breath. NH4+ ions are sequestered in the acidic stomach and 
isotope labelled C02 enters the bloodstream where it is carried to the lungs and 
rapidly expired.  
1.5.2.4  14C – urea breath test 
For this diagnostic test a certain amount of expired CO2 (1 or 2 mmol) is captured in 
a solution that a carbon dioxide trapping agent called hyamine hydroxide. This 
hydroxide is dissolved in either ethanol or methanol, and has thymolphthalein added 
to it as a pH indicator (Henze et al., 1990). Sample readings are taken on a liquid 
scintillation counter. This test is less costly and yet more sensitive than the 13C-UBT, 
however, though radiation doses are relatively low, it remains inappropriate for 
diagnosis in children and pregnant women.  
1.5.2.5   13C – urea breath test 
With this test, a patient fasts overnight and a breath sample of 75-200 mg of 13C- 
urea is given to patient simultaneously with a test meal. Breath sampling is done at 
various time intervals. The amount of labelled CO2 liberated as a result of H. pylori 
urease activity is quantified as the increase in 13CO2/
12CO2 ratio.  
Determining the 13CO2/
12CO2 ratio by isotope dilution mass spectrometry can be very 
difficult due to the high precision required. However, this test has a very high 
sensitivity and specificity when compared to other non-invasive tests and it is the 
only non-invasive test that can detect active H. pylori infection. It is the considered 
the ideal test to determine if treatment was successful in killing the pathogen. Not 
like serology, UBT is extremely accurate in children (Koletzko and Feydt-Schmidt, 
2001).  
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1.6 TREATMENT AND CONTROL 
The colonization of the stomach by H. pylori causes peptic ulcer disease, gastric 
adenocarcinomas and gastric mucosa–associated lymphoid tissue (MALT) 
lymphomas (Chong et al., 2008). The mechanism by which H. pylori stimulates 
peptic ulcer disease is partly understood but is thought to mainly involve a 
combination of virulence factors of the organism (e.g., VacA and CagA proteins), 
genetic predisposition of the host, mechanical injury to the mucosa, and alterations 
of gastric secretions (Cohen, 2000).  
H. pylori infection presents an extraordinary therapeutic challenge. Efforts to 
establish optimal treatment regimens have been thwarted by the fact that the 
pathogen lives in an environment (acidic stomach) not easily accessible to many 
therapeutics. Presently, it is accepted that H. pylori infection is the major culprit in 
peptic ulcer disease and for eradication; most clinicians use a triple drug (at least two 
antibiotics and either bismuth or a proton pump inhibitor) or even quadruple drug 
approach. A proton pump inhibitor is administered in combination with clarithromycin 
or amoxicillin and metronidazole twice daily. These drugs synergize to eradicate the 
bacterium (Malfertheiner et al., 2000).  
In South Africa, the treatment regimen contains clarithromycin, amoxicillin, 
metronidazole and doxycycline and supposedly should exhibit 85 - 95% efficacy 
(Aboderin et al, 2007). Several antibiotics are thus used worldwide to treat H. pylori 
infections, but emerging bacterial antibiotic resistance presents an added challenge 
and continues to plague attempts to eliminate these infections. This problem is a 
very serious public health concern in Africa where there is high prevalence of 
multidrug-resistant strains (Asratet al., 2004; Lwai-lume et al. 2005; Ndip et al., 
2008).  
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Bacterial resistance against the different antibiotics used is common in many 
countries but varies between countries and may even change with time and 
geographical location (Ndip et al., 2008). 
 Moreover, these treatment regimens have put up substantial problems such as high 
cost, adverse side effects and poor compliance amongst patients often leading to 
relapse. (Ndip et al., 2008). These, therefore, result in significant levels of treatment 
failure and contraindications amongst patients. In view of these challenges and other 
obstacles there is need for novel therapeutic approaches to prevent or eliminate H. 
pylori infections using natural products, which have desired anti-bacterial properties 
but at the same time are relatively non-toxic, cheap and have less or no side effects.  
This has led to the re-evaluation of the therapeutic use of honey which is a widely 
used medicine worldwide for the treatment of different disorders, including 
gastrointestinal diseases. Several authors have previously reported that honey inhibit 
the activity of bacteria in vitro and in vivo, and thus possess therapeutic potential 
(Somal et al., 1994; Ali, 1995). Studies with different models of experimentally 
induced acute and chronic gastric lesions in rats have shown the molecular 
mechanisms of honey (Mobarok Ali, 2003).  
The antibacterial properties of honey have been attributed to hydrogen peroxide, 
osmotic effect, low pH, low protein content and non-peroxide factors like flavonoids 
and phenolic acids (Malika et al., 2004). The concentration of these non-peroxide 
components is usually low in the honey but on extraction with organic solvents they 
become more concentrated and thus exhibit increased levels of activity (Aljadi and 
Yusoff, 2003). Consequently, we investigated the effect of honey on Helicobacter 
pylori urease activity. 
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1.7 HONEY 
All the perceived health concerns and genuine limitations with antibiotic use that we 
just described have led to many studies to find alternative treatments. Recently, 
there has been substantial interest in the therapeutic use of honey as an alternative 
treatment. Natural products such as honey have been previously reported to have 
antibacterial activity. Honey is a substance that has been used as traditional 
medicine in a number of customs for decades (Ransome, 1937). The first research 
which demonstrated the antibacterial action of honey was undertaken in 1892 by the 
Dutch scientist Van Ketel. Nowadays, researchers have proven that there are 
several compounds present in honey that possess antibacterial activity (Waikato 
Honey Research Unit 2005).  
 
Figure 1.5 The chemical composition of honey (Source: www.hielschr.com) 
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Honey is a highly concentrated, complicated mixture of carbohydrates, of which the 
monosaccharides form by far the greater part. The composition of honey is very 
complex and differs widely according to its source.  It contains more than 70% 
sugars and less than 20% water. Because of the relatively low water content, the 
caloric value of honey is very high. The overabundance of sugar makes honey 
unstable. 
1.7.1 Mechanism of action 
The mechanism of antimicrobial action of honey is apparently a combination of many 
different modes of action (Molan, 1992a). This antibacterial activity is attributed to its 
high osmolarity, low pH, low water activity, hydrogen peroxide content and other 
uncharacterised compounds. 
1.7.1.1. Glucose oxidase and hydrogen peroxide 
Glucose oxidase (GOx) secreted by bees is an oxido-reductase that catalyses 
oxidation of glucose to form gluconic acid and hydrogen peroxide (H2O2) (Fig. 9) 
(Meyer and Wohlfahrt, 2006). H2O2 is the main antimicrobial agent responsible for 
the antibacterial activity shown in most types of honey (Airborne Honey, 2003). The 
glucose oxidase activity is generally measured by the production of H2O2 and is 
highly variable between different types of honey (Airborne Honey, 2003).  The 
concentration of H2O2 in honey varies and this results in major variations seen in 
overall antibacterial activity of honey (National Honey Board, 2006). Light, room 
temperature, a small amount of visible light and heat (> 50°C) have been found to 
reduce GOx activity (Airborne Honey, 2003). 
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Figure 1.6 The enzymatic reaction catalysed by glucose oxidase (Adapted from Meyer and 
Wohlfahrt, 2006) 
 
H2O2 was initially hailed for its antibacterial and cleansing properties when it was first 
introduced into clinical practice. In more recent times it has lost favor because it 
damages tissue and causes inflammation. However, the H2O2 concentration 
produced in honey when diluted is typically around 1 mmol/l, which is around 1,000 
times less strong than the 3 % solution commonly used as an antiseptic solution but 
is equally effective. It reduces inflammation and does not damage tissue cells. The 
harmful effects of H2O2 are further reduced because honey sequesters and 
inactivates the free iron which catalyses the formation of oxygen free radicals 
produced by H2O2and its antioxidant components help to clear up oxygen free 
radicals. 
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1.7.1.2. Gluconic acid 
Other than carbohydrates, honey contains a variety of amino acids (0.05-0.1%) and 
organic acids (0.57%). Formic, acetic, butyric, citric, formic, gluconic, lactic, maleic, 
oxalic, pyroglutamic and succinic acids have all been identified in honeys (Nelson 
and Mottern, 1931). Gucollic, α-ketoglutaric and pyruvic acids have been found in 
honeys as well (Malika et al., 2004). Honey is mildly acidic with its pH being between 
3.2 and 4.5 (National Honey Board, 2006). The main organic acid present in honey is 
gluconic acid (C6H12O7) that is formed when the first carbon of glucose is oxidised 
(National Honey Board, 2006). The antibacterial activity of honey has been shown to 
be also due to its acidity level. Investigations have shown that it can inhibit most 
bacteria, among them Helicobacter pylori, Escherichia coli, Salmonella spp, 
Pseudomonas aeruginosa and Streptococcus pyogenes (National Honey Board, 
2006).  
Many studies have been done on the antibacterial activity of honey on Helicobacter 
pylori, but there is no information available on the antiurease activity of honey. 
Therefore, one aim of this project was to investigate if honey is an effective inhibitor 
against urease activity. 
 
Figure 1.7 The chemical structure of D-Gluconic acid (Adapted from Wikipedia 
2006e). 
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1.7.1.3. Osmotic effect 
Honey is a supersaturated solution of two monosaccharides (glucose and fructose) 
with a low water activity and high osmolarity. This mixture has a low osmotic 
pressure since most of the water molecules bind with the sugars leaving little 
available to support the growth of microorganisms. Therefore, the high osmolarity is 
a valuable property in the treatment of established infections, because it prevents the 
growth of bacteria (Malika et al., 2004). 
Manuka honey is a high quality honey made in New Zealand by bees which gather 
nectar only from the flowers of the manuka bush. The manuka tree (Leptospermum 
scoparium) is a New Zealand native plant well-known for its medicinal properties 
(Honey New Zealand, 2006). The H2O2 antibacterial property of the active manuka 
honey has higher effectiveness compared to other honeys (Molan, 1992).   
Studies by Allen et al. (1991) on 345 samples of New Zealand honeys from 26 
different floral sources showed that when catalase was added to any of these 
honeys to destroy the H2O2, only manuka honey retained a significant amount of 
antibacterial activity. This meant that manuka honey has an additional bioactivity that 
is not present in other honeys.  
This unique activity was first discovered by Dr. Peter Molan from the Waikato Honey 
Research Unit (Healing Honey, 2005). This bioactivity was named Unique Manuka 
Factor (UMF). It is very stable towards light, heat and body enzymes (Honey New 
Zealand, 2006) and it is also resistant to heat (Waikato Honey Research Unit, 2005). 
The UMF activity subsists in addition to the antibacterial properties of H2O2. 
Collectively, these two factors thus behave synergistically (Waikato Honey Research 
Unit, 2005).  
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Studies have established that UMF effectively inhibits the growth of a wide range of 
bacteria, such as Helicobacter pylori, Staphylococcus aureus, E. coli and S. 
pyogenes (API Health Ltd, 2006). 
1.8 THE PROPOSED INVESTIGATION 
1. The discovery of a potent and safe H. pylori urease inhibitor has been and 
remains a very important area of pharmaceutical research because of the 
cascade of surprisingly simple biological processes initiated by this urease-
producing pathogen in the gastric mucosa. In view of that, the importance of 
urease inhibitors as drugs is enormous given that these molecules can be 
used for treating H. pylori infections.  Nonetheless, up to present, no inhibitor 
has been approved as a drug for use in clinical trials. We will therefore, focus 
our efforts on to investigate new H. pylori urease inhibitors with maximum 
therapeutic impact and minimal side effects. This avenue of research is likely 
to provide answers to many other questions of these inhibitors particularly 
focusing on their type and mechanism of inhibition at the molecular level. 
Moreover, this might as well help deduce the urease mechanism of action 
further. 
2. Several excellent techniques are available to assess urease activity. In this 
work, our approach was to screen new urease inhibitors via a continuous 
spectrophotometric assay which uses glutamate dehydrogenase to couple 
ammonia release to reduced nicotinamide adenine dinucleotide oxidation. 
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1.9  PREVIOUS WORK DONE IN THE RESEARCH GROUP 
In previous years, three locally produced honeys (Pure honey, Citrus blossom and 
Gold crest) from different regions in South Africa were screened for anti-H. pylori 
activity at four different concentrations using the agar well diffusion technique (Manyi 
et al., 2010). All honeys and their solvent extracts demonstrated anti-H. pylori activity 
and were most active at 75% v/v. Chloroform extract recorded the lowest MIC95 
values that ranged from 0.156-5% v/v confirming this extract to be the most active. 
These antibacterial properties were attributed to presence of potential compounds 
with therapeutic activity that could be further exploited as lead molecules in the 
treatment of H. pylori infections (Manyi et al., 2010).  
The observation that these honeys can inhibit the growth of H. pylori is an important 
finding. However, no studies in the world have been reported the antiurease activity 
of honey and its organic solvent extracts on H. pylori isolates, bearing in mind that 
the organism is ubiquitous worldwide, responsible for significant morbidity and 
mortality (Samie et al., 2007) with an increasing trend in antibiotic resistant strains 
(Tanih et al., 2010). Therefore, a survey of different honey varieties (Pure honey and 
Manuka honey) of different geographic origin may reveal a honey with considerable 
antiurease activity since honeys of different geographic origin have different 
antimicrobial activities (Ndip et al., 2007; Basson and Grobler, 2008). For this 
reason, in this study, the main aim was to assess and compare the inhibitory 
potential of Pure honey and Manuka honey extracts on the urease activity of H. 
pylori isolates from South Africa. This could give light to identification of organic 
compounds in honey that are derived from numerous biosynthetic pathways which 
contribute in the aromatic properties of the honey in addition to its floral and 
geographical origin determination. 
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1.10 HYPOTHESIS 
Urease plays an important role in the biological activity of H. pylori. Its inhibition will 
suppress H. pylori activity, consequently reducing the infection.  
1.11 OBJECTIVES OF THIS RESEARCH 
The following principal objectives guided the investigation: 
a. To isolate and study the enzymatic activity of H. pylori urease. 
b. To determine the inhibitory effects of ‘Pure honey’(South Africa) and Manuka 
honey (New Zealand) extracts on the activity of H. pylori urease 
c. To investigate and compare the inhibitory effect of two different varieties of 
honeys of different geographic origin on H. pylori urease 
d. To purify and characterize the H. pylori urease enzyme 
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Chapter 2 : PRODUCTION AND ISOLATION OF H. PYLORI 
UREASE 
 
2.1 INTRODUCTION 
2.1.1 Bacterial growth 
When bacteria are grown in a batch culture, four phases of growth are typically 
observed: 
a) Lag phase - Instantly after inoculation of bacterial cells into fresh medium, the cell 
population remains conditionally unchanged as cells initially adjust to the new 
medium. During this phase cells increase in mass or volume, synthesize enzymes, 
RNA as metabolic activity increases but there is no apparent cell division occurring. 
The length of the lag phase is apparently dependent on several factors such as 
inoculums size, bacterial strain, culturing conditions, time necessary to recuperate 
from shock encountered in the transfer; time required for synthesis of division factors 
(Todar, 2004). 
b) Exponential (log, logarithmic) phase – This physiological state is marked by rapid 
division of cells by binary fission as growth increases by geometric progression. The 
rate of cell division is dependent on growth medium composition and the incubation 
conditions.  
c) Stationary phase – Classically defined as a physiological state where the rate of 
cell division equals the rate of cell death, thus viable cell number remains constant. 
Population growth becomes limited by: exhaustion of available nutrients, 
accumulation of inhibitory metabolites and/or end products and lack of "biological 
space". 
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d) Autolysis (death, exponential/logarithmic decline) phase – If bacterial cells are 
incubated beyond the stationary phase, a death phase follows, in which the viable 
cell population starts to decline as lysozymes are released into the cytoplasm. 
During this physiological state, the number of viable cells decreases exponentially. 
2.1.2 Production of urease by H. pylori 
When bacteria grow under specific conditions they produce the highest percentage 
of the enzyme of interest. Enzymes are usually classified as inducible or constitutive. 
Inducible enzymes are produced in response to the availability of a homologous 
substrate in the culture medium (Todar, 2004). These enzymes are only produced 
when they are needed. Conversely, constitutive enzymes are produced in constant 
amounts without regard to the physiological demand or the concentration of the 
substrate. Therefore, they are not controlled by induction or repression and are 
present in relatively the same concentration in cells at all times. The ability of plants, 
bacteria, fungi, algae and invertebrates to synthesize urease (urea amidohydrolases, 
EC 3.5.1.5) has been studied extensively. The ureases though of different protein 
structures, they are all nickel-containing metalloenzymes that have a single catalytic 
function, urea-hydrolysis to its final products, ammonia and carbonic acid (Karplus et 
al., 1997; Sumner, 1926).  
Amongst the several ureolytic bacteria, of special interest to the scientific community 
are those that are pathogenic to humans and animals. The pathogenesis is due to 
the end products of urea hydrolysis, which bring about pH elevation (up to about 9.2) 
and the toxicity of the released ammonia and its derivatives (Burne and Chen, 2000). 
The substrate urea for the reaction is readily available as a nitrogenous metabolic 
waste product of most terrestrial animals with a serum concentration in humans of 
about 1–10 mM (Burne and Chen, 2000).  
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This makes urea readily available to ureolytic bacteria making the intestinal tract one 
of the most common sites of ureolytic bacteria infections in humans (Burne and 
Chen, 2000). H. pylori is the principal ureolytic bacterium infecting the 
gastrointestinal tract (Burne and Chen, 2000). The bacterium colonizes the mucosal 
lining of the stomach, a highly acidic environment which is considered the first line of 
defense against most gastrointestinal pathogens. It survives in this hostile 
environment by synthesising vast quantities of urease (accounting for about 10% of 
the total protein content of the cell) which hydrolyses urea into ammonia and C02, 
which generate a pH neutral micro-environment (Bauerfeind et al., 1997). 
H. pylori appears unique in that it has the ability to incorporate urease in its outer 
membrane which is strictly cytoplasmic in other bacteria (Hawtin et al., 1990). 
Interestingly, considering that urease is a large oligomeric protein (Austin et al., 
1992) one would normally not expect it to traverse the bacterial outer membrane.  
Though so evident that urease is located on the surface of late log phase H. pylori, 
the mechanisms whereby surface-association occurs have not been clearly 
elucidated. 
2.1.2.1 H. pylori urease as a potential therapeutic target for the treatment 
of gastric infections 
The urease of this gastrointestinal pathogen is a conspicuous biochemical marker 
which can be targeted for intervention therapy. In light of this, urease inhibitors have 
attracted much attention as potential new antiulcer drugs since the virulence of the 
pathogen can be controlled using a substance that inhibits this enzyme’s activity 
(Eaton et al., 1991).  
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2.2 Materials and methods 
2.2.1 Media 
All media were suspended in distilled water, mixed well and dissolved by heating 
with frequent agitation. Boiling was then carried out for about one minute to allow 
complete dissolution. The media was then sterilized in an autoclave at 100 kPa 
(121°C) for 15 minutes.   
2.2.2 Buffers 
The preparation of all buffers is explicitly mentioned in Appendix A.  
2.2.3 Source of micro-organism 
Two strains of Helicobacter pylori, a standard ATCC 43526 (American Type Culture 
Collection, Manassas, VA, USA) and one clinical isolate (H. pylori 369C) cultured 
from gastric corpus biopsy specimen of a patient with gastroduodenal disease 
attending the endoscopy unit of Livingston hospital, Port Elizabeth, Eastern Cape 
Province were used for this study.  Primary isolation of the clinical strains was 
performed on Columbia Blood Agar (Oxoid Ltd, Basingstoke, Hants, UK) 
supplemented with Skirrow’s antibiotics (Appendix B) and de-fibrinated horse blood 
7% (v\v). The plates were incubated microaerophilically (85% N2, 10% CO2 and 5% 
O2) (Helico-Campy Pack gas-generating envelopes, Oxoid Ltd, Basingstoke, Hants, 
UK) at 37oC for 5 days. H. pylori bacteria cells were identified according to colony 
morphology, Gram staining, microaerophilic growth at 37°C, and confirmed by the 
presence of oxidase, catalase, and urease. H. pylori reference strain, ATCC 43526 
was used as positive control. 
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2.2.4 Time course survey 
 For the intracellular and extracellular enzyme determinations to be meaningful, it 
was necessary to standardize on an incubation time that would give as maximum 
levels of the enzyme as possible. The strains were grown in brain heart infusion 
broth supplemented with 10% heat-inactivated horse serum for culture times ranging 
from 24-96  hours at 37oC under microaerophilic conditions (85% N2, 10% CO2 and 
5% O2) (Helico-Campy Pack gas-generating envelopes) on a rotary shaker at 120 
rpm as previously described by Shibata et al (2003). The levels of intracellular and 
extracellular ureases were evaluated in aliquots removed from 24 hr, 48 hr, 72 hr, 
and 96 hr old cultures by monitoring the enzyme activity as established by 
Kaltwasser et al. (1966). The cells that gave the highest urease activities were then 
used for all subsequent experiments in order to prepare the crude cell-free extracts. 
2.2.5 Crude Urease preparations 
The H. pylori cells were harvested by centrifugation (5000 g, 4oC and 20 mins) and 
used for isolation and purification of the intracellular enzyme; whereas the 
supernatant was used for the isolation and purification of the extracellular enzyme. 
2.2.5.1 Extracellular crude urease 
Broth cultures (3 Litres) of 2.0 x 108 CFU/ml were centrifuged (5 000g, 4oC and 10 
mins). The pellet and supernatant were separated and designated PLT1 and SNT1 
respectively. SNT1 was assayed for protein and extracellular urease activity. The 
pellet (PLT1) was washed twice with phosphate-buffered saline (pH 7.4) and used 
for intracellular urease isolation.   
 
65 
 
2.2.5.2 Intracellular crude urease 
H. pylori cells (17.530 g wet weight) (PLT) were resuspended in 100 ml buffer, 
supplemented with Complete, Mini, EDTA-free Protease Inhibitors (Roche 
Diagnostics, South Africa). The suspended cells were divided into 20 Falcon tubes. 
Bacterial cell disruption was achieved using an Omni Sonic Ruptor Ultrasonic 
Homogenizer (Omni International, Kennesaw, USA) on an ice bath.  Following 
centrifugation at 25,000 g for 20 mins at 4oC to remove the cell debris, the 
supernatant obtained was designated SNT 2. This cell free extract was assayed for 
protein concentration and intracellular urease activity. 
2.2.6 Urease activity and protein determination 
2.2.6.1 Protein Determination 
Protein concentrations were determined according to Bradford (Bradford, 1976) with 
bovine serum albumin as a standard (Appendix C). The method relies on the shift in 
maximum absorbance from 465 to 595 nm when Coomassie Brilliant Blue G- 250 
binds to the protein in acid solution. 
2.2.6.2 Urease Assay  
Urease activity was assayed spectrophotometrically by measuring the reduction in 
NADH in the coupled urease-glutamate dehydrogenase (GDH) system using the 
protocol established by Kaltwasser et al. (1966).  
Urea + H2O + 2H
+                                    2 NH4+ + CO2 
2NH4+ + 2α-ketoglutarate + 2NADH          2Glutamate + 2NAD+ +2H2O 
 
Urease 
GLDH 
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The assay cocktail was made up by pipetting the following:  0.1M potassium 
phosphate buffer, pH 7.6 (1.2 ml), 0.023M ADP (0.05 ml), 0.0072M NADH (0.05 ml), 
0.026M α-ketoglutarate (0.05 ml), 1.8M Urea (0.05 ml) and glutamate 
dehydrogenase, 500 Units/ml (0.05 ml) into a cuvette. The assay cocktail was 
equilibrated at 25°C for 10 min prior to the addition of the enzyme preparation.  The 
decrease in NADH absorbance was recorded at 340nm every 30 s for 8 minutes.  
Enzyme Activity Calculation 
The change in absorbance per minute was plotted over the linear range of the curve 
and was used in the calculation of urease activity. One enzyme unit was defined as 
that amount of urease that catalyzes the oxidation of 1 μmol of NADH per minute at 
25°C and pH 7.6. Enzyme activity and specific activity were calculated according to 
equations below.  
 
 
 
6.22 : extinction coefficient of NADH at 340 nm 
The decrease in absorbance at 340 nm, due to the oxidation of NADH, is 
proportional to the ammonia concentration. The ammonia produced reacts with α-
ketoglutaric acid and NADH in the presence of glutamate dehydrogenase to form 
glutamate and NAD+. Glutamate dehydrogenase reacts specifically with ammonia. 
Specific activity of urease was calculated as μmol of urea hydrolysed per min/mg of 
protein. 
Units/ml  =  (∆A340nm/min Test-∆A340nm/min Blank) (Volume of assay, ml) 
(6.22) (Volume of enzyme used, ml) 
 
Units/mg  = Units/ml enzyme 
mg protein/ml enzyme 
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2.2.7  Enzyme location 
H. pylori cells (17.5303 grams wet weight) were harvested as described earlier in 
section 2.2.3. The pellet and supernatant were separated and designated PLT1 and 
SNT1 respectively. SNT 1 and PLT 1 were assayed for protein concentration and 
urease activity. The pellet was then re-suspended in distilled water and then 
disrupted by sonication as described earlier. Cell debris designated (PLT 2) and cell 
free extract designated (SNT 2) were obtained by centrifugation (25,000 xg, 20 mins, 
4oC). PLT 2 and SNT 2 were also assayed for protein concentration and urease 
activity. 
 
2.2.8  Optimization of cytoplasmic urease extraction 
H. pylori cells were harvested as described earlier in 2.2.5.1 to yield a pellet 
(17.5303 grams wet weight). The pellet was washed twice with phosphate-buffered 
saline (pH 7.4) and then re-suspended in buffer. The cells were divided into 10 tubes 
of equal volumes. Five tubes were subjected to sonication on ice at an amplitude of 
40W for times ranging from 1 – 5 minutes. The sonicated samples were 
centrifugated (15,000 xg, 20 mins, 4oC) and the cell free extracts obtained were 
tested for protein concentration and urease activity. The other five tubes were 
subjected to a sonication time of 5 minutes for power amplitudes ranging from 10 – 
50W. The sonicated samples were centrifuged and the cell free extracts obtained 
were assayed for protein concentration and urease activity as described earlier. 
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2.2.9 Statistical analysis 
Throughout the entire study, the test results and data were recorded and analyzed 
using the SAS software Version 9 statistical package. The differences were 
considered significant when the p value was less than 0.05. 
2.3 Results and Discussion 
2.3.1 Time course survey 
A time course survey to determine the highest cytoplasmic and extracellular urease 
activities during the growth of H. pylori was carried out. The highest cytoplasmic 
urease activity was observed at 72 hr (late exponential phase) (Figure 2.1). 
 
Figure 2.1 Production of cytoplasmic and extracellular urease by H. pylori over time. IU 
means intracellular urease whereas EU means extracellular urease.369C – clinical isolate. 
ATCC – reference strain. The data are the average of three experiments and bars indicate 
standard deviations. 
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These findings are similar to previous observations which showed that urease is only 
localized in the cytoplasm during the exponential growth phase in H. pylori in vitro 
cultures (Phadnis et al., 1996). 
The highest extracellular urease activity was observed at 96 hr (Figure 2.1) and this 
corresponds with the stationary phase of H. pylori growth (Phadnis et al., 1996).     
H. pylori cultivated for 96 hrs demonstrated significant amounts of extracellular 
urease activity, probably due to significant amounts of surface-bound enzyme. These 
observations indicate that there is extracellular release of cytoplasmic urease with 
aging cultures. This dependence of urease release on the phase of growth in vitro 
appears to imply that the mechanism of autolysis process is regulated genetically 
(Mobley, 2001). The importance of autolysis in this bacterium’s pathogenesis 
remains an intriguing hypothesis to explain its adaptation to an acidic environment. 
 Probably, older cultures are more virulent than the young ones. If that is the case 
then this indicates that autolysis is sensitive to the phase of growth in H. pylori. 
These observations potentially represent an important mechanism for H. pylori to 
modulate its environment within the host. 
2.3.2  Production of protein during H. pylori growth 
The protein concentrations in the extracellular fraction (SNT 1) and intracellular 
fraction (SNT 2) were evaluated in aliquots removed from 24h, 48h, 72h, and 96h 
cultures by the Bradford assay. A typical profile for biosynthesis of proteins during 
bacterial growth was observed (Figure 2.2). Maximal production of protein was 
obtained during incubation time of 24 – 72 hours.  
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This culture time corresponds to the exponential growth phase of H. pylori (Phadnis 
et al., 1996), in which bacterial cells are increasing hastily as cell proteins (amino 
acids, enzymes, transporter molecules, etc) are synthesized. From the observed 
fluctuations we are to think that there is a regulatory pathway or mechanism that 
controls protein levels within bacterial cells at any given time during their lifetime. 
 This mechanism will likely ensure that the cells produce proteins that are necessary 
for the immediate use at a particular time and those proteins not required at that 
particular time are not produced. This corresponds to work by Todar (2004) who 
illustrates that bacterial cells have developed complex mechanisms for the regulation 
and expression of enzymes.  
 
Figure 2.2 Production of protein by H. pylori over time. IU means intracellular urease 
whereas EU means extracellular urease.369C – clinical isolate. ATCC – reference strain. 
The data are the average of three experiments and bars indicate standard deviations. 
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2.3.3  Localization of urease enzyme 
To allow comparison of the urease activity of the different cell fractions, enzyme 
activity was expressed as a comparative percentage. The whole pellet fraction was 
considered as 100% since it represents the activity of the cell in its natural state. 
Analysis revealed urease activity in both H. pylori strains; urease activity was 
associated with both the cell surface and the cytoplasm. Urease activity showed no 
correlation with localization of activity. 
Figure 2.3 Activity of urease enzyme (72 hr culture) in different cell fractions. 
SNT1=Supernatant before sonication; PLT1= Control (pellet before sonication); SNT2= 
supernatant after sonication; PLT2= pellet after sonication. 369C – clinical isolate. ATCC 
43526 – reference strain. The data are the average of three experiments and bars indicate 
standard deviations. 
 
Our results demonstrate that H. pylori urease is not uniform in all H. pylori strains. 
Because of the differences in activity we are to think that localization of urease 
activity may account for different virulence activities among the strains. 
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2.3.4 Optimization of cytoplasmic urease extraction by sonication 
Optimising enzyme release by sonication is very important. According to the Omni 
Sonic Ruptor Ultrasonic Homogenizer (Omni International, Kennesaw, USA) Manual, 
a power of 50W is the extreme and 40W is recommended for sonication of bacterial 
cells. In this study, sonication was done at 4ºC and the cells were suspended in 
buffer.  
As presented in the graph, a power setting of 40W was used and the exposure time 
to the ultrasound was varied between 1-5 minutes. A time setting of 5 minutes was 
also chosen and kept constant whilst the power applied was varied between the two 
extremes (10- 50W). 
 
Figure 2.4 Sonication effects on urease activities. The data are the average of three 
experiments. 
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The sonication conditions that resulted in the most significant urease activity were 
found to be amplitude of 40W and a time of 4 minutes. A power setting of 20W and 
exposure time of the cells for 5 minutes also gave significant enzyme activity though 
slightly lower (Figure 2.7). From enzyme activity values presented above it shows 
that doubling the power from 20W to 40W and increasing exposure time from 4 
minutes to 5 minutes only increases urease activity by about 5.6%. 
% difference   = (3.6 - 3.41)/3.41*100% 
   = 5.6 % 
For this reason, the best sonication conditions were thought to be amplitude of 20W 
and a time of 5 minutes. In any case it would be better to choose a lower amplitude 
as to minimize the risks of enzyme denaturation as heat is generated during the 
process which would reduce the sonication efficiency.  
We also found some observation of interest. The recommended machine input is 
40W for bacterial samples and the urease activity is also highest at 40W implying 
that there could be a resonance effect. Resonance is when the frequency of 
oscillations of the input signal equals the natural frequency of the substance being 
investigated. 
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2.4  Conclusions 
In summary, the following conclusions were deduced from this chapter: 
a. Maximum extracellular urease activity is attained on culturing for 96 hr. 
b.  Maximum intracellular urease activity is attained on culturing for 72 hr. 
c. Maximal production of protein is obtained during the exponential phase of H. 
pylori in broth cultures (24 – 72 hr). 
d. The significant urease activity observed after sonication of the cells indicates 
that the enzyme is mainly located in the cytoplasm. 
e. Sonication conditions that release the greatest amount of enzyme into the 
supernatant are a power of 20W and a time of 5 minutes but however 
denaturation of enzyme cannot be ruled out. 
The findings of the optimal time at which maximum urease is produced by H. pylori 
led to the experiments conducted in Chapter 3 and Chapter 4. 
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Chapter 3 : PURIFICATION AND CHARACTERIZATION OF H. 
PYLORI UREASE 
 
3.1 Materials and Methods 
3.1.1 Materials 
The lyophilized urease of specific activity ≥ 5 Units/mg protein was obtained from 
Merck (South Africa (Pty) Ltd).  The Glutamate dehydrogenase (GLDH)  from bovine 
liver of specific activity 40 Units mg−1 protein, NADH, ADP, α-ketoglutaric acid,  urea 
and acetohydroxamic acid were all obtained from Sigma-Aldrich Co. (South Africa 
(Pty) Ltd). All the chemicals were of analytical grade and were prepared in 0.10 M 
Phosphate buffer, pH 7.6. Protease inhibitors (Complete mini EDTA-free) were 
purchased from Roche Diagnostics (Pty) Ltd, South Africa.  Horse serum was from 
Oxoid Ltd (Hampshire, UK). Dialysis tubing (cellulose membrane, 10 kDa MWCO), 
SDS-PAGE standard markers (Prosieve QuadColor Protein ™ Markers; 4.6 – 
300kDa, Maine, USA), Brilliant Blue R-Staining Solution (B-6529), acrylamide, N, N - 
methylene-bis-acrylamide were also purchased from Sigma-Aldrich Co. (South Africa 
(Pty) Ltd). 
3.2 Purification methods  
3.2.1 Bacterial Culture 
Two strains of Helicobacter pylori, a standard ATCC 43526 and one clinical isolate 
(H. pylori 369C) cultured from gastric corpus biopsy specimen of a patient with 
gastroduodenal diseases attending the endoscopy unit of Livingston hospital, Port 
Elizabeth, Eastern Cape Province were cultured and harvested as previously 
described (Sections 2.2.3). 
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3.2.2 Harvesting of cells and preparation of cell free extracts 
Cell free extracts (CFE) were obtained as described earlier in section 2.2.5 of 
Chapter 2 and purified. 
3.2.3 Urease activity and protein determination 
3.2.3.1 Protein Determination 
Protein concentrations in the cell free extracts and purified enzyme fractions were 
determined in replicates according to Bradford (Bradford, 1976) with bovine serum 
albumin as a standard as previously described (Appendix C).  
 3.2.3.2 Urease Assay  
Urease activity was assayed spectrophotometrically by measuring the reduction in 
NADH in the coupled urease-glutamate dehydrogenase (GDH) system as described 
earlier in Section 2.2.6.2 of Chapter 2. 
3.2.4 Cell-free extract concentration 
Concentration of the crude extract is necessary prior to protein purification using 
chromatographic techniques, in order to increase protein content and decrease the 
volume. Two extract concentration methods were employed in this study. The cell-
free extract (100 ml) was divided into two equivalent parts designated CFE1 and 
CFE2; CFE1 was concentrated by ammonium sulfate precipitation and CFE2 by 
freeze drying. Several attempts were made in this study before best results could be 
obtained.  
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3.2.4.1 Ammonium Sulfate Precipitation 
CFE1 (50 ml) was precipitated by slow addition of solid ammonium sulfate to 70% 
saturation (Appendix E) with constant stirring on a magnetic stirrer at room 
temperature over a period of 30 min. The precipitates were separated by 
centrifugation (10 000 g, 4°C and 30 min). Then the precipitated proteins were re-
suspended in 10ml of 0.1M potassium phosphate buffer (pH 7.6) and dialyzed 
against excess of the same buffer. This dialysate was designated as ammonium 
sulphate fraction (ASF) and was analyzed for protein concentration and urease 
activity. 
3.2.4.2 Concentration by freeze-drying 
CFE2 (50 ml) was transferred into a freeze-drying flask and frozen by gently swirling 
the flask in acetone. The freeze-drying flask was then transferred onto a freeze dryer 
(New Brunswick Scientific Co, New Jersey, USA) and the extract freeze dried at        
- 70°C overnight. The powdered extract was weighed and re-suspended in 6 ml of 
potassium phosphate buffer (0.1 M, pH 7.6) (1:2 w/v) and assayed for protein and 
urease activity. This fraction was designated as freeze-dried fraction (FDF). 
3.2.4.3 Dialysis 
The two concentrated samples were sealed in dialysis tubing (Pierce Biotechnology, 
Rockford, Illinois, USA) and dialyzed overnight in 10 times sample volume potassium 
phosphate buffer (0.1M, pH 7.6) to ensure complete removal of ammonium sulfate 
and contaminating salts. The samples were assayed for protein and urease activity. 
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3.2.5 Chromatographic instrument 
A fast protein liquid chromatography, AKTA-FPLC system (pump P-900, monitor 
UPC-900 and fraction collector Frac-900) with ultra-violet (UV), conductivity and pH 
sensors was used. Protein detection was done by reading absorbance at 280nm. 
The system was controlled by Unicorn software version 5.1 installed on the 
computer. Sample injection was done using a sample loop (Pharmacia). Fractions 
were collected automatically according to obtained UV reading peak values. 
3.2.6 Column chromatography 
All purification steps were carried out at room temperature (ca. 25°C), and the 
urease activity of every fraction collected was evaluated as described in Section 
3.2.6.2. The purified enzyme fraction was obtained after one-step procedure 
described next. 
3.2.6.1 Size-exclusion chromatography on Superdex 200 pg 
Concentrated samples (4 ml each) from ammonium sulphate precipitation and 
freeze-drying were applied separately onto a HiLoad 16/60 Superdex 200 pg (GE 
Healthcare). The column was pre-washed with gel-permeation buffer [1X: (50mM 
NaH2PO4 , 150mM NaCl, 1 mM EDTA); pH 7] and equilibrated until A280 of elute had 
reached baseline. The flow-rate was set at 1 ml /min and samples were eluted with 
the same buffer. Fractions (1 ml) eluted at 1 ml min-1 were screened for urease. 
3.2.6.2 Urease Activity Selection 
After the chromatography run, each fraction (20 µl) was mixed with testing buffer 
(300 µl) composed of 3 mM NaH2PO4, 110 mM urea, and 7 µg ml
-1 phenol red 
adjusted to pH 7.6 in a 96-well microtiter plate using a multichannel pipette. To blank 
wells, chromatography buffer (20µl) was added. The plate was incubated at 37ºC. 
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Quantitative determination of the absorbance at 560 nm was done in a microplate 
reader (SynergyMx, BioTek Instruments, USA) by serial measurement at different 
time points for up to 20 min. 
3.2.6.3 Urease specific activity determination 
Determination of protein content in the fractions was done according to Bradford 
(Bradford, 1976) with bovine serum albumin as a standard as previously described 
(Appendix C). Urease specific activity was determined spectrophotometrically using 
the coupled urease-glutamate dehydrogenase (GDH) system as described earlier in 
Section 2.2.6.2 of Chapter 2.  
3.2.7 Determination of purity 
To monitor the progress of purification of the enzyme, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) was performed on samples 
exhibiting urease activity. Samples (25 μl) from each purification step and a standard 
molecular weight maker (4.6 – 300 kDa, Merck, South Africa) were applied on 12% 
SDS-PAGE (Appendix D) and electrophoresed at 200 V for 50 minutes. The gels 
were stained with Coomassie Brilliant Blue R-250 Staining solution (Appendix D), 
then destained in acetic acid, methanol and water (1:3:6 v/v/v) destaining solution 
overnight (Appendix D). The distance moved by the partially purified protein was 
measured and its corresponding molecular weight calculated from the calibration 
curve of log molecular weight versus distance migrated (Appendix D). 
 
82 
 
3.3  Results and Discussion  
3.3.1  Purification of Urease  
Each concentrated extract was filtered through a 0.45 µm-pore-size filter. Each 
filtrate was then subjected to size-exclusion chromatography on a HiLoad 16/60 
Superdex 200 pg column, which has a separation range of Mr 10 000 - 600 000, and 
a Vo of 40 ml. The fractions were screened for urease. The fractions that were 
urease-positive were pooled and assayed for activity. 
The purification of urease from our isolate, H. pylori 369C was compared with the 
purification of urease from the reference strain, H. pylori ATCC 43526. In attempting 
to concentrate and purify urease we employed freeze-drying and fractional 
precipitation with ammonium sulphate. The effect of these two concentration 
methods on urease activity was thus investigated. Several attempts to concentrate 
the 369C urease with ammonium sulphate precipitation resulted in significant loss of 
enzyme activity; as a result freeze drying was the preferred method for the 
purification of the 369C. On the other hand the ATCC 43526 urease that was 
concentrated by fractional precipitation with ammonium sulphate had higher enzyme 
activity than the ATCC 43526 urease concentrated with freeze-drying thus it was 
chosen for purification of the ATCC 43526. 
3.3.1.1 Size-exclusion chromatography of 369C enzyme extract after 
freeze-drying  
The chromatogram in Fig. 3.1 starts with the injection of the sample and shows the 
absorbance at 280 nm. The maximum urease activity was found in the first peak 
(45.57 ml retention). The other contaminating peaks apparently indicative of several 
other different proteins were not further characterized.   
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Figure 3.1 Size-exclusion chromatography of 369C urease after freeze-drying on a HiLoad 
16/60 Superdex 200 prep grade column equilibrated with running buffer (50mM NaH2PO4, 
150mM NaCl, 1 mM EDTA); pH 7] at a flow-rate of 1 ml/min. indicates pooled fractions. 
 
After the size-exclusion chromatography, urease-positive fractions were pooled, 
evaluated for protein content and assayed for activity. Using this data, specific 
activity, fold purification and enzyme recovery were calculated. The results of this 
purification are summarized in Table 3.1. 
Table 3.1 Urease purification from H. pylori strain 369C 
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The crude enzyme extract obtained by sonication containing 133.8 mg total protein 
and 7144.92 µmol/min total activity was concentrated by freeze drying. Purification 
by freeze drying increased the specific activity from 53.4 to 89.0 µmol of urea 
hydrolysed/min/mg as water was removed creating more concentrated areas of 
solute (urease). The marked decrease in protein concentration from 133.8 to 43.87 
mg is also an indication that contaminating proteins were removed. The freeze-dried 
extract had higher levels of activity than the extract concentrated by ammonium 
sulphate fractionation perhaps because very low levels of heat are involved in 
freeze-drying. The dialysis step removed salts from the buffer and other small 
molecules that had been freeze dried. This technique increased specific activity from 
89.0 to 95.4 and the fold purification from 1.46 to 1.54. This slight increase in urease 
activity is probably as a result of salts removal from enzyme extract. The size-
exclusion step removed most of the contaminating proteins as shown by a marked 
increase in specific activity (from 95.4 to 203.7 µmol of urea hydrolysed/min/mg.  
 
3.3.1.2 Size-exclusion chromatography of ATCC 43526 enzyme extract 
after ammonium sulphate fractionation 
The chromatogram in Fig. 3.2 starts with the injection of the sample and shows the 
absorbance at 280 nm.  
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Figure 3.2. Size-exclusion chromatography of ATCC 43526 urease after ammonium 
sulphate precipitation on a HiLoad 16/60 Superdex 200 prep grade column equilibrated with 
running buffer (50mM NaH2PO4 , 150mM NaCl, 1 mM EDTA); pH 7] at a flow-rate of 1 ml 
/min. indicates pooled fractions. 
 
The maximum urease activity was found in the first peak (44.53 ml retention). The 
other several peaks which are suggestive of several other different proteins were not 
further characterized. For this urease from the reference strain, ATCC 43526, the 
urease-positive fractions were pooled, evaluated for protein content and assayed for 
activity as well. The results of this purification are summarized in Table 3.2. 
Table 3.2 Urease purification from H. pylori strain ATCC 43526 
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Fractional precipitation of ATCC 43526 crude extract with ammonium sulphate 
increased the specific activity from 46.8 to 98.6 µmol of urea hydrolysed/min/mg 
(Table 3.2). Ammonium sulphate draws water molecules away from the non-polar 
units of the proteins. This decrease in available water molecules increases the 
surface tension and enhances hydrophobic interactions, thus allowing the protein to 
precipitate from a solution. The fold purification increased from 1 to 2.107.  
Ammonium sulphate maintains the protein in a folded state and also its low heat of 
solubilisation avoids the risk of protein denaturation that can occur when the sample 
temperature increases. The dialysis step removed salts and ions (that may limit the 
activity of the enzyme) through osmosis from a highly concentrated solution (enzyme 
extract) to the dilute solution (buffer).  
This is supported by the purification fold which increased from 2.107 to 2.280. The 
Superdex 200 pg step ‘cleaned up’ the target protein as shown by the significant 
increase in specific activity (from 106.4 to 264.7 µmol of urea hydrolysed/min/mg). 
From both purification tables of the urease from the two H. pylori strains there was a 
noticeable drop in the enzyme recovered as a result of the size-exclusion step. 
However, chromatography on Superdex 200 pg does significantly increase the fold 
purification based on protein thus indicating that this is a high yield method of 
purification of this enzyme. 
The two concentration methods gave concentrates of almost the same activity and 
had almost the same retention times when chromatographed on Superdex 200 pg. 
The first peak that was found with the freeze dried extract (369C) should be the 
same enzyme that is present in the first peak of the ammonium sulphate fractionated 
extract (ATCC 43526).  
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Confirmatory studies were performed with SDS-PAGE to determine the molecular 
weight of the urease enzyme. 
3.3.2  SDS-PAGE molecular weight analysis 
The ureases purified from this study were derived from two different strains: 369C        
(a clinical isolate from a hospital in South Africa) and ATCC 43526.  
3.3.2.1 Purified urease from H. pylori ATCC 43526 
The molecular weight markers, crude extract, and ASF extract were loaded in lanes 
1, 2 and 3 respectively, while lane 4 was loaded with pooled fractions obtained from 
the Superdex 200 pg chromatography.  
 
Figure 3.3 SDS-PAGE (12 %) analysis of purified urease from H. pylori ATCC 43526. Lane 
1: Molecular weight markers. Lane 2: Crude extract. Lane 3: Ammonium sulphate 
fractionation (ASF) extract. Lane 4: Pooled fractions (Tubes 45 – 48) from Superdex 200 pg 
size exclusion. Lane 5: Fraction 45. Lane 6: Fraction 46. Lane 7: Fraction 47. Lane 8: 
Fraction 48. 
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A faint band at molecular weight 63.5 and 30.3 kDa was seen (Figure 3.3) with the 
pooled fractions from the size-exclusion chromatography, while very distinct bands 
were observed in the crude extract (obtained after sonication) and the ammonium 
sulphate fraction (ASF). The molecular weight values of these subunits are 63.5 and 
30.3 kDa. The values are similar to those reported by Dunn et al. (1990) and Hu and 
Mobley, 1990).  
3.3.2.2 Purified urease from H. pylori 369C 
The molecular weight markers, crude extract, and freeze-dried extract were loaded 
in lanes 1, 2 and 3 respectively, while lane 4 was loaded with pooled fractions 
obtained from the Superdex 200 pg chromatography.  
No bands were seen (Figure 3.4) with the pooled fractions from the size-exclusion 
chromatography (Lane 4). However, like with the other electrophoretogram, two 
distinct bands were observed in the crude extract (obtained after sonication) and 
freeze drying. The bands observed correspond to molecular weight values of about 
60 and 26.5 kDa. Lanes 5 – 8 which are representatives of Fraction 43 – 46 showed 
distinct bands at molecular weight values of 60 and 26.5 kDa. Surprisingly with the 
pooled fractions (Lane 4), no band could be visualized. Another SDS gel was run but 
to no avail, no bands were visualized in Lane 4 (pooled fractions). This suggests 
probable contamination during loading of samples. There are also bands of 
molecular weight values of about 315 kDa appearing in Lanes 2 and 3 on both 
electrophoretograms.  
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Figure 3.4 SDS-PAGE (12 %) analysis of purified urease from H. pylori 369C. Lane 1: 
Molecular weight markers. Lane 2: Crude extract. Lane 3: Freeze-dried extract. Lane 4: 
Pooled fractions (Tubes 43 – 46) from Superdex 200 pg size exclusion. Lane 5: Fraction 43. 
Lane 6: Fraction 44. Lane 7: Fraction 45. Lane 8: Fraction 46. 
 
This observation is probably caused by aggregation of urease forming 
macromolecular assemblies which is in agreement with previous studies (Austin et 
al., 1991). This postulation is also supported by the fact that Superdex 200 pg has a 
separation range of Mr 10,000 – 600,000. 
3.4 Summary 
Urease purification from H. pylori proved successful. Total protein and enzyme 
activity decrease with each step in enzyme purification, starting with low levels of 
urease activity probably left minute amounts of the urease after Superdex 200 pg 
size exclusion chromatography.  
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Other likely reason for the low yield or recovery in this purification might be the 
nature of the source for the microorganism and proteolysis during the course of the 
study. Though protease inhibitors were introduced in the crude extract, proteolysis 
cannot be ruled out.  
Although all the purification procedures were performed at low temperatures, 
degradation of the target protein cannot be ruled out during the course of the study. 
In spite of all these challenges, appreciable levels of purification are shown in the 
purification tables.  
3.5 Conclusions 
 
1. The urease of H. pylori purified in this study is a multimeric enzyme composed 
of polypeptide subunits. These subunits were in agreement with those 
previously reported for H. pylori urease. 
2. We can safely conclude that the molecular weights of ureases of H. pylori are 
similar and quite independent on the particular culture of the bacteria and 
culturing conditions. 
3. Ureases in different strains tend to be uniformly distributed in the H. pylori. 
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Chapter 4 : INHIBITORY POTENTIAL OF HONEY ON H. PYLORI 
UREASE ACTIVITY 
 
4.1  Enzyme inhibition kinetics 
 Several substances can bring about a reduction in the rate of an enzyme catalysed 
reaction. Some substances are non-specific protein denaturants (e.g. urea) whereas 
others act in a quite specific manner and are known as inhibitors (e.g. cyanide and 
heavy metals). The loss of enzyme activity may be either reversible, when the 
activity may be restored by the removal of the inhibitor, or irreversible, when the loss 
of enzyme activity is time-dependent and cannot be recovered during the timescale 
of interest (Copeland, 2000). Therefore enzyme inhibitors fall into two broad classes: 
those causing reversible inactivation of enzymes (reversible inhibitors) and those 
whose inhibitory effects can be un-reversed (irreversible inhibitors).  
4.1.1 Reversible inhibitors 
A typical property of all reversible inhibitors is that when the inhibitor concentration 
falls, the enzyme activity is regenerated. These inhibitors typically bind to enzymes 
by non-covalent forces and the inhibitor keeps up a reversible equilibrium with the 
enzyme. Reversible inhibitors fall into four classes: competitive inhibitors, non-
competitive inhibitors, uncompetitive and mixed inhibitors (Meleti, 1986). 
4.1.1.1 Competitive inhibitors 
The substrate and competitive inhibitors both compete and bind at the same active 
site. If the inhibitor binds in the enzyme active site, then the enzyme does not react 
with its substrate.  
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This kinetic behaviour can be shown as: 
 
Scheme 1: Adapted from Bugg (2004) 
Where:  
E is the active enzyme; 
I is the inhibitor  
EI is the reversible enzyme-inhibitor complex 
KI is the inhibition constant  
KS is the thermodynamic constant 
4.1.1.2 Non-competitive inhibitors 
The non competitive inhibitor and substrate react at different active sites. 
 
Scheme2: Adapted from Bugg (2004) 
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4.1.1.3 Uncompetitive inhibitors 
Uncompetitive inhibition occurs when the inhibitor binds only to the enzyme–
substrate complex, not to the free enzyme; the EIS complex is catalytically inactive.  
 
Scheme 3: Adapted from Bugg (2004) 
4.1.1.4 Mixed inhibitor 
 Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of 
the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors interfere with substrate 
binding (increase KM) and hamper catalysis in the ES complex (decrease Vmax). 
 
Scheme 4: Adapted from Bugg (2004) 
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4.1.2  Irreversible inhibitors 
Unlike reversible inhibitors that dissociate from the enzyme, an irreversible inhibitor 
forms a covalent bond with the enzyme molecule and does not dissociate. As shown 
below, irreversible inhibitors form a reversible non-covalent complex with the enzyme 
(EI) and this then reacts to produce the covalently modified complex,  EI’. 
 The rate at which EI’ is formed is thus the inactivation rate or kinact. The enzyme is 
therefore permanently inactivated due to the irreversible interaction between the 
inhibitor and enzyme. 
 
Scheme 5: Adapted from Bugg (2004) 
where:  
E is the active enzyme and I is the inhibitor  
EI is the reversible enzyme-inhibitor complex  
EI’ is the irreversible enzyme-inhibitor complex  
KI is a thermodynamic constant that describes the affinity of the inhibitor for the 
active zone of the enzyme  
kinac is a kinetic constant that describes the rate of binding of inhibitor to the enzyme 
active site.  
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4.2 Materials and methods 
3.2.1 Materials 
The commercial enzyme (Jack Bean urease) and substrate (urea) were purchased 
from Merck (South Africa (Pty) Ltd). A locally produced natural honey called “Pure 
Honey” (Multiflora, non-irradiated, 100% SA dawn, Bee farms) was purchased from 
Port Alfred, South Africa. Manuka honey was purchased from Littleover Apiaries 
(Derbyshire, New Zealand). Chloroform and Diethyl-ether were purchased from 
Merck (South Africa (Pty) Ltd) and were of analytical grade. 
4.2.2 Solvent extracts preparation 
Chloroform was used for extraction of ‘Pure Honey’ and Diethyl-ether was used for 
extraction of Manuka honey. The extraction of each honey sample was performed 
using the method adapted from Zaghloul et al. (2001). The crude honey (100g) was 
diluted with sterile distilled water (150 ml) in a 500 ml flask. The diluted crude honey 
was successively extracted with 150 ml of solvent in three steps using 50 ml of 
solvent each time. The mixture was shaken for 15 min for each extraction process. 
The mixture was then allowed to stand to allow separation of the solvent layer from 
the aqueous layer. The aqueous layer was returned to the flask and another batch of 
the same extraction solvent (50 ml) was added and extracted for 15 min. This was 
done as three successive extractions. The solvent layers from each extraction 
process were pooled, and filtered over anhydrous sodium sulfate to remove water 
contaminating extracts. The solvent extract was concentrated by evaporation with a 
rotary evaporator (Steroglass, Strike 202, Padua, Italy), under reduced pressure at 
40ºC. The extracts were kept at room temperature prior to the urease inhibition 
assay.  
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4.2.3 Urease Inhibition  
The solvent extracts were tested for their inhibitory effects on partially purified 
intracellular ureases. The intracellular ureases used for inhibition studies were those 
isolated previously in Chapter 2. One extracted from the clinical isolate (H. pylori 
369C) and the other from ATCC 43526. The Jack bean urease was used as control. 
4.2.3.1 Why focus on the inhibition of intracellular urease? 
It was speculated that extracellular urease is involved in acid resistance of the 
bacterium (Krishnamurthy et al., 1998). However, studies by Marcus and Scott, 2001 
have shown that urease is a cytoplasmic protein, but it is then found on the surface 
of stationary-phase bacteria probably due to lysis of a subpopulation. These 
investigators have put through strong arguments that extracellular urease does not 
contribute to acid resistance of H. pylori and that the enzyme is irreversibly 
inactivated at gastric pH levels (less than 4). Since it is now widely accepted that 
intracellular urease protects H. pylori against acidity and not extracellular urease we 
thus decided to focus only on the inhibition of intracellular urease. 
4.2.3.2 Urease Assay  
Urease activity was assayed spectrophotometrically by measuring the reduction in 
NADH in the coupled urease-glutamate dehydrogenase (GDH) system as described 
earlier in Section 2.2.6.2 of Chapter 2. 
4.2.3.3 Urease Linearity Assays 
A certain volume of assay buffer [0.1 M Phosphate buffer, pH 7.6] was added to a 
solution of ADP (100 μL, 0.023 M), NADH (100 μL, 0.0072 M), ketoglutarate (100 μL, 
0.026 M), urea (100 μL, 1.8 M) and GLDH (100 μL, 500 Units/ml) in a UV cuvette, 
followed by the addition of aliquots (0 to 100 μL) of urease which started the 
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reaction. The assay buffer volume was adjusted to give a constant total assay 
volume (3000 μL). The spectrophotometer was set to measure the decrease in 
absorbance at 340nm, at 30s intervals for 5 mins at 25°C as described earlier in 
Chapter 2 (Section 2.2.6.2). All of the urease linearity assays were carried out in 
triplicate. 
4.2.3.4 Urea Dependence Assays 
A solution of urea (0 to 100 μL, 1.8 M) was added to a certain volume of assay buffer 
in a UV cuvette containing the other assay cocktail components: ADP (100 μL, 0.023 
M), NADH (100 μL, 0.0072 M), ketoglutarate (100 μL, 0.026 M), urea (100 μL, 1.8 M) 
and GLDH (100 μL), followed by the addition of a certain volume of urease which 
started the reaction. The assay buffer volume was adjusted to give a constant total 
assay volume (3000 μL). The spectrophotometer was set to measure the decrease 
in absorbance at 340nm, at 30s intervals for 5 mins at 25°C as described earlier. All 
of the urea dependence assays were also carried out in triplicate. 
4.2.3.5 Urease Inhibition Assay using Honey Solvent Extracts 
Acetohydroxamic acid was used as the standard inhibitor of urease. The commercial 
urease was also used as the standard enzyme. The partially purified urease isolated 
from the ATCC 43526 strain and the H. pylori 369C were incubated in the assay 
cocktail with honey extracts in potassium phosphate buffer prior to the reading. A 
solution of urease was mixed with varying volumes of the honey chloroform extract. 
Aliquots were then added to a certain volume of assay buffer (adjusted to give a 
constant total assay volume of 3000 μL) in a UV cuvette containing the other assay 
cocktail components as described earlier. The reaction was started by addition of the 
substrate, urea (100 μL, 1.8M). The buffer solution (3000 μL) was used as the blank 
and acetohydroxamic acid (50 μL) was used as the control.  
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The spectrophotometer was set to measure the decrease in absorbance at 340nm, 
at 30s intervals for 5 mins at 25°C. The inhibition percentage (I %) for each solvent 
extract tested was calculated by comparing the NADH oxidation rate before and after 
incubation with the solvent extract according to: 
I (%) = A0 – Ai/A0 × 100 
where A0 is the NADH decrease in absorbance rate with urease activity (no solvent 
extract addition), and Ai represents that rate after incubation with solvent extract. The 
reaction rate was taken from the linear range of the absorbance reading as the slope 
of the linear regression curve. The concentration of inhibitor required to diminish 
enzyme activity by 50% was calculated by plotting percent inhibition against the 
concentration of inhibitor. One hundred percent activity was expected to be 
determined in the absence of inhibitor. Each assay was carried out in triplicate. 
4.2.3.6 Effect of pre-incubation time on the inhibition of urease activity 
The effect of pre-incubation time on the inhibition of urease activity was determined 
by the pre-incubation of the enzyme with test solution (honey extract) at 10 minutes 
intervals for 1 hr prior to addition of substrate  and all other assay components 
required for measuring urease activity. Comparisons of reaction rates in the 
presence of inhibitor with those for control reactions were used to calculate the 
degree of enzyme inhibition each time. 
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4.2.3.7  Determination of IC50 
The main objective of this work is to explore the inhibitory potential of honey extracts 
on the activity of urease. The inhibitory potential of an inhibitor is described either as 
the concentration of an inhibitor at which the enzyme activity falls to 50% of its 
original value or as the molar concentration of the compound required to inhibit 50% 
of the urease activity (IC50). In order to determine the IC50 values (50% inhibition), 
honey extracts (inhibitors) were diluted in phosphate buffer to concentration ranging 
from 20% (v/v) to 100% (v/v). 
4.2.3.8 Determination of the type of enzyme inhibition 
Determination of the inhibition type is critical for identification of mechanism of 
inhibition and the sites of inhibitor binding. One method was applied to monitor the 
effect of inhibitor (solvent extracts) on both Km and Vmax values. This was done by 
plotting the reciprocal of the rate of the reactions against the reciprocal of the 
substrate concentration as Lineweaver-Burk plot. The Dixon plot for urease at 
different urea concentrations was also constructed.  
4.2.4 Characterization of intracellular Urease of H. pylori 
4.2.4.1 pH optimum  
To establish the optimum pH for the partially purified urease, activity was determined 
at different pH values. Urease preparations were made in different buffers of pH 
varying from 2 - 11. The different buffers used at varying pH were:  sodium citrate 
(pH 2 – 5, 0.1 M); potassium phosphate buffer (pH 6 – 8, 0.1 M) and bicarbonate 
buffer (pH 9 – 11, 0.1 M). The urease activity was determined as described in 
Chapter 2 (2.2.6.2).The determination of enzyme activity was done in triplicate at 
each pH. 
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4.2.4.2 Temperature optimum   
The temperature profile for the partially purified urease was determined over a 
temperature range of 4 – 100°C at the pH optimum. The urease activity was 
determined as described in Chapter 2 (2.2.6.2). The determination of enzyme activity 
was done in triplicate at each temperature. 
4.2.4.3 Thermal stability  
To determine the optimal thermal stability of the urease, extracts were heated at 25, 
45, and 65°C for 1 h at the pH optimum. Aliquots were withdrawn from each extract 
at 10 min intervals and assayed for urease activity. Samples were prepared in 
triplicate and residual enzyme activity was measured as described in Chapter 2 
(2.2.6.2).  
4.2.4.4 Estimation of kinetic parameters (Km and Vmax) 
Under all conditions described in this thesis the rate of urea hydrolysis was found to 
be linear with time or under steady state conditions. The kinetic properties of H. 
pylori intracellular urease were determined by varying the substrate (urea) 
concentration from 100 – 2400 mM. Urease activity was determined at each 
substrate concentration and Lineweaver-Burk double reciprocal plots were 
constructed showing relationship between substrate and enzyme activity.  
4.3  RESULTS AND DISCUSSION 
 Kinetic studies were carried out to explore the catalytic activity of urease extracted 
from our H. pylori clinical isolate (369C) in the presence of urea and the potential 
inhibitors (honey extracts). The activity was compared against a commercial Jack 
bean urease (control) and the urease extracted from ATCC 43526 (reference strain).  
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4.3.1  Cytoplasmic urease linearity 
The linear range of the intracellular urease was determined from assays in which the 
enzyme concentration was varied while keeping the substrate concentration constant 
at 1.8M (Figure 4.1). This assay was generated from duplicate assays in which the 
enzyme was varied from 0 to 1.0 mg ml-1 using a constant substrate concentration of 
1.8 M, at 25oC and pH 7.6. A plot of the resulting data (Figure 4.1) shows linearity up 
to 1 mg ml-1 in the concentration of urease. A urease concentration of 1 mg ml-1 was 
therefore selected for all subsequent assays, while the pH and temperature were 
kept constant at 7.6 and 25oC, respectively. 
 
Figure 4.1 Plot of v0 versus urease concentration for determining the linearity dependence 
of urease. The data points represent the mean of triplicate assays. 
  
103 
 
4.3.2 Urease substrate dependence 
To explore the substrate dependence of urease, assays were run with a series of 
substrate concentrations ranging from 10 mM – 2400 mM whilst keeping the urease 
concentration constant at 1 mg ml-1. These assays were run in triplicate at constant 
temperature of 25oC and a pH of 7.6.  
 
Figure 4.2 Michaelis Menten plot of H. pylori (369C) urease, H. pylori (ATCC 43526) urease 
and Jack bean urease. The data points represent the mean of triplicate assays. 
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4.3.3  Effect of pre-incubation time on the inhibition of urease activity 
The results presented in Fig 4.5 and 4.6 shows that urease inhibition by honey 
extracts was independent of incubation time at the concentrations used. When 
urease extract was incubated with the test solutions (honey extracts) at 25oC for 10 
minute intervals for 1 hr, the decrease in activity was insignificant. When urease 
extract was incubated with a well-known inhibitor, acetohydroxamic acid, the 
decrease in activity with time was insignificant as well. Each point represents the 
mean ± S.D. of three experiments. Concentration of honey extract was 100% (v/v). 
 
Figure 4.3 Time dependence of the inhibition of urease by chloroform extract of Pure honey. 
Negative controls were CHCI3 and 369C urease (with no extract of Pure honey). Positive 
control was acetohydroxamic acid (AHA). Concentration of honey extract was 100% (v/v). 
Each point represents the mean ± S.D. of three experiments.  
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 10 20 30 40 50 60 70 
%
 R
e
m
a
in
in
g
 a
c
ti
v
it
y
 
Time (minutes) 
Extract of Pure honey CHCI3 AHA No honey 
105 
 
 
Figure 4.4 Time dependence of the inhibition of urease by diethyl-ether extract of Manuka 
honey. Negative controls were (C2H5)2O and 369C urease (with no extract of Manuka 
honey). Positive control was acetohydroxamic acid (AHA). Concentration of honey extract 
was 100% (v/v). Each point represents the mean ± S.D. of three experiments.  
 
Usually, when the inhibitor binds the enzyme there is formation of covalent bonds. 
The formation of these bonds by the honey extracts however does not display any 
time dependency. The degree of inhibition does not seem to increase with time after 
the honey extracts interacts with the enzyme. This behaviour alone indicates that the 
honey extracts are unlikely to be irreversible inhibitors. 
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4.3.4  Effect of inhibitors 
The two honey extracts were examined in a series of urease inhibition assays. All 
assays were run in triplicate at pH 7.6 and 25oC. The effect of varying the 
concentration of these potential inhibitors on the activity of urease was explored. We 
observed that (Figure 4.7): 
i. Both honey extracts possess some inhibitory effects on urease activity.  
ii. Both extracts inhibited urease activities in a concentration dependent manner.  
 
Figure 4.5 Concentration dependence of urease inhibition. Negative controls were CHCI3, 
(C2H5)2O and 369C urease (no honey extract added). Positive control was acetohydroxamic 
acid (AHA). The data are the average of three experiments and bars indicate the standard 
deviations. 
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4.3.5 Inhibition activities against urease 
 
Although enzymes that are purified are easier to work with than the crude 
preparations it should be remembered that in purifying the enzyme we are removing 
it from its natural environment. Since we are studying the urease in order to gain 
some understanding of how it is involved in the acid resistance mechanisms of H. 
pylori at a molecular level, it was important to keep the conditions as close as 
possible to the conditions within the cell. For these reasons we compared the 
inhibitory activities of the honey extracts against both the crude urease extract and 
the purified urease. 
 
4.3.5.1 Inhibition of crude urease by extract of Pure Honey 
 
The extract derived from Pure honey was screened for enzyme inhibition activities 
against crude urease forms (H. pylori ATCC and H. pylori 369C). Commercial Jack 
bean urease was used as a control. 
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Figure 4.6 Effect of Pure Honey chloroform extract on crude urease activity. Concentration 
of honey extract was 100% (v/v). Jack bean urease and urease produced by H. pylori ATCC 
43526 were used as controls. The data are the average of three experiments and bars 
indicate the standard deviations. 
 
As shown in Figure 4.8, Pure Honey extract was found to be a relatively more potent 
inhibitor for H. pylori 369C urease (I=48%) than for H. pylori ATCC urease (I=42%). 
The extract of Pure honey was shown to be slightly active against purified Jack bean 
urease (control) giving 13% inhibition. 
4.3.5.2 Inhibition of crude urease by extract of Manuka Honey 
 
 The extract derived from Manuka honey was screened for enzyme inhibition 
activities against crude urease forms (H. pylori ATCC and H. pylori 369C). 
Commercial Jack bean urease was used as a control. 
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Figure 4.7 Effect of Manuka Honey diethyl-ether extract on crude urease activity. 
Concentration of honey extract was 100% (v/v). Jack bean urease and urease produced by 
H. pylori ATCC 43526 were used as controls. The data are the average of three experiments 
and bars indicate the standard deviations. 
 
Manuka Honey extract was found to be a comparatively more effectual inhibitor for 
H. pylori ATCC urease (I = 51%) than for H. pylori 369C urease (I = 45%). The 
extract of Manuka honey also exhibited slight inhibitory activity against purified Jack 
bean urease (control) giving 11% inhibition. 
 4.3.5.3 Inhibition of purified urease by extract of Pure Honey 
The extract derived from Pure honey was also screened for enzyme inhibition 
activities against the urease forms (H. pylori ATCC and H. pylori 369C) obtained 
from Superdex 200 pg size exclusion chromatography. Commercial Jack bean 
urease was used as a control. 
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Figure 4.8 Effect of Pure Honey chloroform extract on purified urease activity. Concentration 
of honey extract was 100 % (v/v). Jack bean urease and urease produced by H. pylori ATCC 
43526 were used as controls. The data are the average of three experiments and bars 
indicate the standard deviations. 
 
The extract of Pure Honey was found to be a relatively weak inhibitor for purified 
forms of the enzymes. The extract shows 17% inhibition for H. pylori 369C urease 
and 14% inhibition for H. pylori ATCC urease (Figure 4.10). The extract was also a 
very weak inhibitor against the control enzyme, Jack Bean urease giving an inhibition 
percent of 11.3.  
4.3.5.4 Inhibition of purified urease by extract of Manuka Honey 
The extract derived from Manuka honey was also screened for enzyme inhibition 
activities against the urease forms (H. pylori ATCC and H. pylori 369C) obtained 
from Superdex 200 pg size exclusion chromatography. Commercial Jack bean 
urease was used as a control. 
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Figure 4.9 Effect of Manuka Honey diethyl-ether extract on purified urease activity. 
Concentration of honey extract was 100 % (v/v). Jack bean urease and urease produced by 
H. pylori ATCC 43526 were used as controls. The data are the average of three experiments 
and bars indicate the standard deviations. 
 
The extract of Manuka Honey was also found to be a relatively weak inhibitor for 
both purified forms of the enzymes. The extract gives 16.3% inhibition for H. pylori 
369C urease. The extract was shown to be slightly active against purified H. pylori 
ATCC urease giving 21% inhibition (Figure 4.11). However, the extract was also a 
very weak inhibitor against the control enzyme, Jack Bean urease giving an inhibition 
percent of 13.4.  
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4.3.5.5 Comparison of inhibitory activity in crude enzyme and purified 
enzyme 
 
On comparing the inhibitory activities of the honey extracts against the crude urease 
extract and the purified urease we found some interesting observations. Both honey 
extracts gave higher inhibition percentages when tested with the crude forms of both 
ureases than with the purified forms of the enzymes (Figure 4.8, 4.8, 4.10 and 4.11). 
 The extracts of both honeys have no significant urease inhibitory activity when 
tested with the purified forms of all ureases (Figure 4.10 and 4.11). Higher inhibition 
percentages associated with crude forms of the enzymes may be due to several 
reasons. For instance, when the cell was disrupted, the resulting lysate might have 
had marked changes resulting in substantial changes in the concentrations of the 
various metabolites which made up the crude enzyme preparation.  
Cellular reactions cannot be ruled out on sonicating the cells.  For instance, on 
sonication of the cells, free radicals are generated in the cavitation bubbles which 
then react with other molecules. These substances and other impurities might be 
responsible for the inhibition of the enzyme activity that was observed, however, 
these high inhibition percentages may also indicate interesting and unusual 
properties of the enzyme itself. On the other hand, on sonication of the cells there 
are also several tightly associated enzymatic activities which may affect urease 
activity in vitro bringing about false inhibition. 
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Recommendations  
From observations of this study it can safely be concluded that these two honeys 
exhibit antiurease activity in vitro. Since crude enzyme extracts more closely 
resembles the physiological conditions of the cell than the pure forms of the enzyme 
then the high inhibition percentages associated with crude enzyme forms are 
applicable. In addition, with crude extracts, the enzymes interact with many other 
substances that are undoubtedly subject to physiological control mechanisms which 
are lost if one is to purify the enzyme. As of such, in the purified urease, there are 
very few proteins that are associated with the enzyme structure. It is speculated that 
the purification procedures might have altered the properties of the enzyme in a way. 
It is therefore recommended further studies to investigate if the properties of the 
enzyme were altered in any way after the purification steps. 
4.3.6 Determination of IC50 
 
Pure Honey exhibits an IC50 value greater than 100% (v/v) as shown in Figures 4.8 
and 4.10. Manuka Honey exhibits an IC50 value greater than 100% (v/v) for H. pylori 
369C urease (Figure 4.9 and Figure 4.11) whereas the extract inhibited activity of 
urease isolated from ATCC 43526 strain by 51% (Figure 4.9) In order to establish 
the type of inhibition involved, Lineweaver-Burk was constructed using the 
concentrations of the extract that gave up to about 50% residual enzyme activity. In 
this study Manuka honey extract (100%, v/v) inhibited activity of urease isolated from 
ATCC 43526 strain by 51% thus it was used to determine the type of enzyme 
inhibition involved. 
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4.3.7 Determination of the type of enzyme inhibition 
 
The nature of inhibition of urease activity by extract of Manuka honey was predicted 
from Lineweaver-Burk (Figure 4.12) and Dixon plots (Figure 4.13). Lineweaver-Burk 
plot indicated several possibilities for the type of inhibition. As of such we decided to 
ignore the values for bigger dilutions since chances of error are high with such 
dilutions. On ignoring such dilutions, the Lineweaver-Burk plot now indicated a 
urease inhibition that seemed to be mixed inhibition. However, the Dixon plot 
confirmed the Manuka honey extract to be a competitive inhibitor. 
 
Figure 4.10 Lineweaver-Burk plot representing reciprocal of initial velocity versus reciprocal 
of urea concentration in the absence and presence of Manuka honey extract (50% (v/v) and 
100% (v/v)) at pH7.6. The data are the average of three experiments. 
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The Dixon plot indicated a different nature of urease inhibition by the extract of 
Manuka honey. The plot reveals the inhibition to be competitive, a behavior where 
the substrate and the inhibitor compete for the enzymatic site binding. This 
characteristic of competitive inhibitors is shown by the lines converging above the x 
axis (Figure 4.13), thus the honey extract is a competitive inhibitor. Therefore, it is 
speculated that there are some honey components that probably share structural 
resemblances with the substrate urea. 
 
Figure 4.11 Dixon plot for ATCC 43526 urease at four urea concentrations in the absence 
and presence of Manuka honey extract at pH 7.6. The data are the average of three 
experiments. 
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4.3.8 Characterization studies  
Since urease serves as the basis of detection of H. pylori in gastric biopsies and 
represents an important virulence factor, biochemical characteristics of the enzyme 
were determined. 
4.3.8.1 pH profile 
The activity of most enzymes strongly depends on the pH of the medium; therefore it 
was important to optimize the pH of urease. Since urease has been found in diverse 
species and in diverse environmental conditions the pH profile were explored using 
different buffers over a range of 4 – 10.  
 
Figure 4.12 pH optimum of H. pylori 369C urease. The data are the average of three 
experiments and bars indicate standard deviations. 
 
The pH optimum of urease was found to be 7.5 (Figure 4.14). This finding is in 
agreement with previous observations of pH optima by other investigators who 
reported it to be 8.2 (Mobley et al., 1988) and 7.4 (Sigh et al., 1990). 
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4.3.8.2 Temperature profile  
The optimal temperature for urease at pH 7.5 was 40°C (Figure 4.15). This finding is 
similar to previous observations of temperature optima of other ureases; 45°C 
(Mobley et al., 1988) and 43°C (Mobley et al., 2001) from Campylobacter pylori and 
H. pylori respectively. The temperature profile represents a typical shape which is 
typical of enzyme kinetics whereby the rate of enzymatic reaction increases as 
temperature increases. However, at higher temperatures there is disruption of the 
enzyme structure and subsequent denaturation of the enzyme.  
 
Figure 4.13 Temperature optimum of H. pylori 369C urease. The data are the average of 
three experiments and bars indicate standard deviations. 
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4.3.8.3 Thermal stability 
Thermostability study was performed and exhibited that the urease in the crude 
extract was highly stable until to a temperature of about 40 oC (Fig. 4.16). 
 
Figure 4.14 Thermal stability profile of H. pylori 369C urease. The data are the average of 
three experiments and bars indicate standard deviations. 
 
When the temperature rose above this the urease was highly unstable that are no 
factors in the crude extract that we had thought would stabilize the enzyme against 
thermal shock. 
4.3.9 Estimation of kinetic parameters (Km and Vmax) 
The Michaelis-Menten plots clearly shows that at low substrate concentrations the 
rate of reaction increases more or less linearly with the substrate concentration 
while, at higher substrate concentrations the reaction rate becomes constant. The 
Michaelis constant, Km, can be obtained by interpolation since it is the substrate 
concentration at which the reaction rate is half of its maximum value (Vmax/2), which 
is the reason why Km is also called the half-saturation value.  
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However, it is difficult to specify the exact substrate concentration corresponding to 
Km from this hyperbolic plot. For this reason, Lineweaver-Burk plots were used 
because they allow accurate measurements of the values of both Km and Vmax even 
at higher substrate concentrations. 
 
Figure 4.15 Lineweaver-Burk plot of H. pylori 369C urease. The data are the average of 
three experiments. 
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Figure 4.16 Lineweaver-Burk plot of H. pylori ATCC 43526 urease. The data are the 
average of three experiments.  
 
 
Figure 4.17 Lineweaver-Burk plot of Jack bean urease (control). The data are the average 
of three experiments. 
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From these plots, the following Km and Vmax were found: 
Table 4.1 Kinetic parameters of urease. 
Enzyme Km (mM) Vmax (µmol/min/ml) Literature 
values 
References 
Jack bean 
urease 
3.43 190.41 2.9 -3.6 Blakeley et al.1969 
Dixon et al. 1980 
Krajewska et al.1999 
H. pylori ATCC 
43526 urease 
40.07 98.25 0.2 – 0.8 Mobley et al. 1988 
Hu and Mobley (1990) 
Dunn et al. 1990 
H. pylori 369C 
urease 
61.11 45.32   
 
In this study, crude ureases were tested for kinetic properties. Jack bean urease, a 
commercial purified enzyme was used as a control. Generally, Km values can be 
obtained from crude cell extracts. In this study, we found that the urea Km values of 
purified H. pylori ureases from literature did not agree with the values observed for 
crude cell extracts. A possible explanation for this is that some buffers interfere with 
urease activity and therefore leads to inaccurate Km determinations. Thus, different 
values can be reported as the Km values vary with buffer, pH and assay conditions.  
We also reported different Km values for the two strains of H. pylori. This observation 
indicates that different strains of the same species possess different Km values 
(Table 4.1). 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Helicobacter pylori infects about half of the world’s population (Go, 2002). Infection 
by this bacterium is the main cause of various gastric diseases such as gastritis, 
gastric lymphoma, peptic ulcers, and stomach cancer (Go, 2002). The fact that the 
organism is ubiquitous worldwide, responsible for significant morbidity and mortality, 
and is intricate to eradicate makes it a prime target for novel therapeutic approaches.  
However, the advancement of successful eradication therapies based on typical 
antibiotics has shown to be very problematic seeing that though treatment regimens, 
have confirmed rational levels of eradication, the occurrence of strains resistant to 
these antibiotics is a serious cause of concern. The regimens have also put up 
substantial problems such as adverse side effects and poor compliance amongst 
patients (Ndip et al., 2008). In view of these challenges and other obstacles that 
plague attempts to eliminate H. pylori infection, novel therapeutic regimens are 
essential and urease inhibitors may play a role in these future therapies. 
To date, several urease inhibitors have been discovered. Although most of them 
exhibit great pharmoco dynamic and pharmaco kinetic properties they have not been 
used for therapeutic purposes because of their adverse effects and toxic effect in 
vivo (Xiao et al., 2007; Von Kreybig et al., 1968). For these reasons, much attention 
now focuses on exploring the novel urease inhibitory activities of natural products 
because of their low toxicity and good bioavailability.  
Natural products like honey have been used since primeval times in folk medicine all 
over the world due to its many biological properties such as antitumor, antioxidant, 
antimicrobial and anti-inflammatory among others (Meda et al., 2005).  
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In light of this research, honey has been found to inhibit Helicobacter pylori growth in 
vitro. The mechanism by which honey inhibits this bacterium’s growth has not been 
fully elucidated. Since urease is one of the major virulence factors in the 
pathogenesis of this bacterium, investigations on the effect of honey solvent extracts 
on the enzyme activity were carried out. This current study investigated the potential 
of honey to inhibit urease activity of H. pylori. 
It can be concluded from this study that, the chloroform extract of “Pure honey” 
showed stronger inhibition of urease activity than the diethyl ether extract of “Manuka 
honey”. Further studies are needed to isolate and identify the active compounds from 
the solvent extracts of these honeys. The sonication conditions which gave the best 
extraction method of urease from H pylori were found to be at low amplitude (20W) 
and a time five minutes. Urease was found to be both surface-associated and 
cytoplasmic. After identifying and optimizing the extraction of both forms of the 
enzyme, a time course survey was carried out to determine optimal time at which 
highest enzyme production occurs. Maximum cytoplasmic urease activity was found 
to occur after 72 hr whereas maximum extracellular urease activities were found to 
occur after 96 hr. 
Following this, solvent extracts of two honeys from different geographical locations 
were tested for their inhibitory effects on partially purified intracellular ureases. We 
observed that both honey extracts possess some inhibitory effects on urease activity. 
The effects of varying concentrations of these extracts on the activity of urease at pH 
7.6 and 25oC was then explored. It was found that both extracts inhibited urease 
activities in a concentration dependent fashion. The two honey extracts were also 
examined in a series of urease inhibition assays to explore the effect of pre-
incubation time on the inhibition of urease activity.  
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It was found that enzyme inhibition was independent of incubation time.‘Pure Honey’ 
extract showed to be a more potent inhibitor for 369C urease (I = 48%) than for 
ATCC urease (I = 42%) and the control, Jack bean urease (I = 13.3 %). Whereas, 
Manuka Honey extract showed to be a fairly more potent inhibitor for ATCC urease  
(I = 51.3%) than for 369C urease (I = 45 %) and the control, Jack bean urease         
(I = 11%). The kinetic data indicates that these extracts inhibit urease in a non-
competitive manner. The inhibitory activities of these two honeys from different 
geographical locations were thus almost similar. These honeys did not display any 
uniqueness toward the inhibition activities. 
After isolation it was necessary to purify and characterize the urease enzyme and 
two strategies were used and compared. The purification was done for ureases from 
both strains (H. pylori 369C and the reference strain, H. pylori ATCC 43526). The 
369C urease concentrated by freeze drying had one peak containing urease activity 
on Superdex 200 pg with a specific activity of 203.7 µmol of urea hydrolysed/min/mg 
and a purification fold of 14.3. The ATCCC 43526 urease concentrated by 
ammonium sulphate precipitation also had one peak containing urease activity on 
Superdex 200 pg with a specific activity of 264.7 µmol of urea hydrolysed/min/mg 
and a purification fold of 5.66.  
Analysis of the fractions from both strains by a 12% SDS-PAGE showed three 
distinct bands of molecular sizes which are in the same magnitude as other ureases 
purified from H pylori. Characterisation studies also showed that H. pylori 369C 
urease operates optimally at a pH of 7.5 and temperature of 40°C. Kinetic 
parameters Km and Vmax for substrate urea were found to be 61.11 mM and 45.32 
µmol/min/ml respectively. 
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The overall objective of the present study was to inhibit urease activity using a 
urease extract, however, experiments conducted using the crude urease were not 
able to give IC50 at concentrations below 100% (v/v). The most likely explanation 
could be that the solvent honey extracts were not pure enough to effectively bring 
about inhibition. This problem can be overcome by isolation of pure compounds from 
the active fractions. From the important results of this study, it can be suggested that 
the screening against urease using urease inhibitory assay is a useful tool to guide 
the separation and purification process of the active urease inhibitor compounds 
from honeys from different geographic locations. The honey varieties are important 
and promising natural resources for the discovery of novel bioactive compounds 
such as natural urease inhibitors which have the potential to become safe and 
powerful anti-H. pylori drugs. 
Future work involves 
1. Establish further H. pylori urease purification with high yield and purity. 
2.  The chromatographic analysis of the pure compounds from the active 
fractions. 
3. Establish the enzymatic mechanism for the inhibition of urease by the pure 
compounds from honey extracts. 
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APPENDICES 
 
Appendix A: Buffers 
A1: Phosphate - buffered saline (pH 7.4) 
 NaCI    8g 
 KCI    0.2g 
 Na2HPO4   1.44g 
 KH2PO4   0.24g 
 Deionized water  800ml 
Adjust pH to 7.4 with HCI/NaOH before filling up to 1litre with deionized water. Store 
at 4 oC. 
A2: Potassium phosphate buffer (0.1M, pH 7.6) 
 1M K2HPO4   86.6 ml 
1M KH2PO4   13.4 ml 
Deionized water  900ml 
Adjust pH to 7.6 with HCI/NaOH before filling up to 1litre with deionized water. Store 
at 4 oC. 
A3: Na-citrate buffer (0.1M, pH 5.5) 
 0.1M Citric acid  4.7 volumes 
 0.1 M Na3 citrate  15.4 volumes 
A4: Sodium bicarbonate (1M) 
Na2CO3   132g 
Deionized water  900ml 
This was made up to 1 litre with deionized water. 
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A5:  Gel-permeation buffer (50mM NaH2PO4 , 150mM NaCl, 1 mM EDTA); pH 7) 
NaH2PO4   5.999g 
NaCl    8.766g 
EDTA    0.372g 
Deionized water  900ml 
Adjust pH to 7 with NaOH before filling up to 1litre with deionized water. Store at 4 
oC. 
A6: Urease screening buffer [(3 mM NaH2PO4, 110 mM urea, 7 µg ml
-1 phenol 
red), pH 7.6] 
NaH2PO4   0.360g 
Urea    6.607g 
Phenol red   0.007g 
Deionized water  900ml 
Adjust pH to 7.6 with NaOH before filling up to 1litre with deionized water. Store at 4 
oC. 
Appendix B: Skirrow’s antibiotics preparation 
The antibiotic supplement was prepared per vial. To rehydrate the contents of the 
vial 2 ml of sterile distilled water was added followed by mixing well to dissolve. 
Aseptically the contents of the vial were added to 500 ml of sterile, molten Columbia 
Agar with 7% v/v defibrinated horse blood.  
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Appendix C: Method of protein determination - Bradford assay (Bradford, 1976) 
C1: Protein stock solution (2mg/ml) 
Dissolve 0.02g of Bovine serum albumin (BSA) in 10 ml of ddH2O. 
C2: Protein standard curve 
Different protein concentrations were prepared from the BSA stock solution (2mg/ml) 
as shown in Table A1. A protein standard curve was generated by reading the 
absorbance of these different concentrations at 595nm (Figure I). For the test 
sample, 3ml Bradford reagent was added to 0.1ml diluted sample and the 
absorbance read at 595nm. 
Table C1: Preparation of protein standard curve 
Tube Protein 
concentration 
(mg/ml) 
BSA  
Stock solution  
(2 mg/ml) 
(ml) 
Buffer(ml) Bradford 
reagent(ml) 
1 0 0 1 3 
2 0.25 0.125 0.875 3 
3 0.50 0.250 0.750 3 
4 0.75 0.375 0.625 3 
5 1.00 0.500 0.500 3 
6 1.25 0.625 0.375 3 
7 1.50 0.750 0.250 3 
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Figure I Protein Standard Curve. 
 
Appendix D: Methods used for purification and partial characterization of 
Helicobacter pylori urease  
D1 SDS-PAGE 
Solution A: Acryl amide stock solution (30% acryl amide, 0.8% bis-acryl amide). 
Weigh 29.2g acryl amide and 0.8g bis-acryl amide, and then dissolve in 100ml de-
ionized water and stir until acryl amide powder is completely dissolved. Store in the 
dark at 4 °C. 
Solution B: 10% (w/v) SDS – Dissolve 10g SDS in 90 ml water with gentle stirring 
and bring to 100 ml with deionized water. 
Solution C: 4x Separating Gel buffer – Add 75ml of 2M Tris-HCl buffer (pH 8.8) 
and 4ml of 10% SDS and then make up the volume to 100ml with deionized water. 
Solution D: 4X Stacking Gel buffer – Add 50ml of 1M Tris-HCl buffer (pH 6.8) and 
4ml 10% SDS, and make up the volume to 100ml with deionised water. 
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Solution E: 10% Ammonium per sulphate solution (APS) - Dissolve 0.5g 
ammonium persulfate in 5ml deionised water. 
Solution F: Electrophoresis buffer – Add together 3g Tris base, 14.4g glycine and 
1g SDS. Dissolve all three in 1 litre of deionised water. 
Solution G: 5× Sample buffer – Add together 0.6ml 1M Tris-HCl buffer (pH 6.8), 
5ml 50% glycerol, 2ml 10% SDS, 0.5ml 2-mercaptoethanol, 1ml 1% bromophenol 
blue, and make up the volume to 10ml with deionised water. 
Solution H: Coomassie blue staining solution – Dissolve 1.0g Coomassie Blue 
R250 in a mixture of 450ml methanol, 450ml deionised water and 100ml glacial 
acetic acid. 
Solution I: Coomassie Gel Destain solution – Add together 100ml methanol, 
100ml glacial acetic acid and 800ml de-ionized water. 
Table D1 Recipe for Resolving Gel 
 Solutions Volume (μl) 
DDI H2O 3400 
30% Stock Acryl amide 4000 
1.5M Tris- HCl pH 8.8 2500 
10% (w/v) SDS 100 
10% Ammonium per Sulphate 50 
TEMED 5 
 
Table D2 Recipe for stacking gel 
Solutions Volume (μl) 
DDI H2O 6100 
30% Stock Acryl amide 1300 
0.5M Tris- HCl pH 6.8 2500 
10% (w/v) SDS 100 
10% Ammonium per Sulphate 50 
TEMED 10 
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Appendix E. Calculation of the number of grams of ammonium sulphate (g) to 
add to 1 litre sample to give desired concentration (per cent saturation) 
 
g  =  533 (S2 – S1) 
100 – 0.3 S2 
 
S1: Starting concentration 
S2: Final concentration 
 
